| Title of Invention | NOVEL SUBSTITUTED INDOLES HAVING SEROTININ RECEPTOR AFFINITY USEFUL AS THERRAPEUTIC AGENTS PROCESS FOR THEIR PREPERATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
|---|---|
| Abstract | The present invention relates to the compounds represented by general formula (I) as shown below. |
| Full Text | Novel substituted indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them. Field of Invention: The present invention relates to the compounds described by general formula (I), including the stereoisomers, radioisotopes, N-oxides, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, bio-active metabolites or any suitable combination of the above chemical forms of compounds defined by general formula (I). The present invention also includes the process for preparing such compounds of general formula (I). These processes also include some additional steps that may be required to obtain the stereoisomers, the radioisotopes, the N-oxides, the polymorphs, the pharmaceutically acceptable salts, the pharmaceutically acceptable solvates, bio-active metabolites and also includes any suitable combination of the above. There are variety of methods to administer the compounds of general formula (I), and such suitable pharmaceutically acceptable dosage forms and the use of such compounds and compositions in either therapy or diagnosis also form the part of this invention. Background of the Invention The compounds of this invention are useful in modulating the function of G-protein-coupled receptors (GPCRs). Majority of drugs exerts their action by interacting with GPCRs, which results into pharmacologically beneficial effect. The mode and general functioning of GPCRs is well understood and can be found in the literature. (References : Bohm S. K., and et. al., Biochem. J. (1997), 322, 1 - 18; McConalogue, Karen, and Nigel W. Bunnett., G-Protein-Coupled Receptors in Gastrointestinal Physiology. II. Regulation of neuropeptide receptors in enteric neurons. Am. J. Physiol. 274 (Gastrointest. Liver Physiol. 37): G792-G796,1998.) The compounds of general formulae (I), are useful in treating neuropsychiatric diseases which involve receptors, modulated by ligands such as 5-HT (Serotonin), melatonin and dopamine, in order to obtain the desired therapeutic effect. International Patent Publications WO 04/000205, WO 04/000845, WO 04/000849, (Suven Lifesciences Limited) describes a few of related prior art. These PCT applications and the references reported therein are all incorporated herein. The compounds of general formula (I) are useful in treating the psychotic, affective, vegetative and psychomotor symptoms of schizophrenia and the extrapyramidal motor side effects of other antipsychotic drugs; neurodegenerative disorders like Alzheimer's disease, Parkinson's and Huntington's chorea and chemotherapy-induced vomiting; and in modulation of eating behavior and thus are useful in reducing the morbidity and mortality associated with excess weight. International Patent Publication WO 03/066056 A1 reports that antagonism of S-HTe receptor could promote neuronal growth within the central nervous system of a mammal. Summary of the Invention: The present invention relates to the compounds of general formula (I), their stereoisomers, their radioisotopes, their N-oxides, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, their useful bio-active metabolites and also includes any suitable combination of the above. The compounds of general formula (I) are defined as follows, General Formula (I) wherein A may be either a -CR11R12-, -0=0, -SO2-, -(CO)NH- or -C=S group. Q may be either a -CR11R12-, -C=0, -SO2-, -(CO)NH- or -C=S group, Ri, R2, R3, R4, R5, Re, R7. Rs, R9, R10, R11, R12, Ri4and R15 may be same or different and each independently represent hydrogen, halogen, 0x0, thio, perhaloalkyi, hydroxy, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (CrCi2)alkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (C3-C7)cycloalkyl, (C3"C7)cycloalkenyl, bicycloalkyi, bicycloalkenyl, (Ci-Ci2)alkoxy, cyclo(C3-C7)alkoxy, aryl, aryloxy, aralkyi, aralkoxy, heterocyclyl, heteroaryl, heterocyclylalkyi, heteroaralkyi, heteroaryloxy, heteroaralkoxy, heterocyclylalkyioxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl, aryioxycarbonyi, aralkoxycarbonyi, heterocyclylalkoxycarbonyl, heteroaryloxycarbonyl, hydroxyalkyi, aminoalkyi, monoalkylaminoalkyi, dialkylaminoalkyi, alkoxyalkyl, aryloxyalkyi, aralkoxyalkyi, alkylthio, thioalkyi, alkoxycarbonylamino, aryloxycarbonylamino, aralkyloxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkylamidino, alkylguanidino, dialkylguanidino, hydrazine, hydroxylamino, carboxylic acid and its derivatives, sulfonic acids and its derivatives, phospiioric acid and its derivatives; or the adjacent groups like Ri and R2 or R2 and R3 or R3 and R4 or R5 and Re or Re and R7 or R7 and Re or Re and R9 together with carbon atoms to which they are attached may form a five or a six membered ring, optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms; or Rn and R12 together with the carbon atoms to which they are attached may form a three to six membered ring, optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms, Ri3, R16 and R17 may be same or different and each independently represents hydrogen, substituted or unsubstituted groups selected from linear or branched (d-Ci2)alkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkenyl, bicycloalkyi, bicycloalkenyl. aryl, aralkyi, heteroaryl excluding 2-pyridyl and 4-pyridyl, heterocyclylalkyi; alternatively R13 along with either R16 or R17 and the two nitrogen atoms may form a 5-, 6- or 7- membered heterocyclic ring, which may be further substituted with Ri4and R15, and may have either one, two or three double bonds, "n" is an integer ranging from 1 to 4, wherein the carbon chains which "n" represents may be either linear or branched. Partial list of such compounds of general formula (I) is as follows: 1-Benzenesulfonyl-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(4-Fluorobenzenesulfonyl)-2-(4-methylpipera2in-1-ylmethyl)-1H-indole; 1-(4-lsopropylbenzenesulfonyl)-2-(4-methylpipera2in-1-ylmethyl)-1H-indole; 1-(4-Methoxybenzenesulfonyl)-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1"(2-Bromo-4-methoxyben2enesulfonyl)-2-(4-methylpipera2in-1-ylmethyl)-1H-indole; 1 -(4-Methoxybenzenesulfonyl)-5-methoxy-2-(4-methylpiperazin-1 -ylmethyl)-1 H- indole; 1"(4-Methoxybenzenesulfonyl)-5"methoxy-2"(4-methylpiperazin-1-ylmethyl)-1H-indole Hydrochloride salt; 1-(4-lsopropylbenzenesulfonyl-5-methoxy-2-(4-methylpiperazin-1-ylmethyl)"1H- indole; 3"Chloro-1-(4-isopropylbenzenesulfonyl-5-methoxy-2-(4-methylpiperazin-1-ylmethyl)-1 H-indole; 1-(4-lsopropylbenzenesulfonyl-5-methoxy-2-(4-methylpiperazin-1-ylmethyl)-1HH'n Hydrochloride salt; 3-Chloro-1-(4-methoxyben2enesulfonyl)-5-methoxy-2-(4-methylpipera2in-1-ylmethyl^^ 1H-indo!e; 3-Chloro-1-(4-methoxyben2enesulfonyl)-5-methoxy-2-(4-methylpiperazin-1-ylmethyl)- 1H-indole Hydrochloride salt; 1-(2-Bromobenzenesulfonyl)-2-(4-methylpipera2in-1-ylmethyl)-1H-indole; 1-(2-Bromobenzenesulfonyl)-3-chloro-2-(4-methyIpiperazin-1-ylmethyl)-1H-indole; N-(1-Benzenesulfonyl-1H-indol-2-yl)methyl-N,N\N'-trimethylethylene-1,2"diamine; N-(1-Benzenesulfonyl)-3-bromo-1H-indol-2-yl)methyl-N,N\N'-trimethylethylene-1,2- diamine; N-(1-(4-Methylben2enesulfonyl)-1H-indol-2-yl)methyl"N,N\N'-trimethylethylene-1,2- diamine; 1-(2-Bromo-4-methoxybenzenesulfonyl-1H-indol-2-yl)methyl-N,N',N' trimethylethylene-1,2-diamine; 1-(2-Bromo-4-methoxybenzenesulfonyl-3-chloro-1H-indol-2-yl)methyl-N,N',N'- trimethylethylene-1,2-diamine, hydrochloride; [1-BenzenesulfonyHH-indol-2-yl]-(4-methylpiperazin-1-yl)methanone; [1-(4-Fluorobenzenesulfonyl)-1H-indol-2-yl]-(4-methylpiperazin-1-yl)methanone; [1-(4-lsopropylbenzenesulfonyl)-1H-indol-2-yl]-(4-methylpiperazin-1-yl)methanone; [1-(4-Methoxybenzenesulfonyl)-1H-indol-2-yl]-(4-methylpiperazin-1-yl)methanone; [1-(2-Bromo-4-methoxybenzenesulfonyl)-1H-indol"2-yl]-(4-methylpiperazin-1- yl)methanone; [1-(4-Methoxybenzenesulfonyl)-5-methoxy-1H-indol-2-yl]-(4-methylpiperazin-1- yl)methanone; [1-(4-lsopropylbenzenesulfonyl)-5-methoxy-1H-indol-2-yl]-(4-methylpiperazin-1- yl)methanone; [3-Chloro-1-(4-isopropylbenzenesulfonyl)-5-methoxy-1H-indol-2-yl]"(4- methylpiperazin-1-yl)methanone; [3-Chloro-1-(4-Methoxybenzenesulfonyl)-5-methoxy-1H-indol-2-yl]-(4- methylpiperazin-1-yl)methanone; [1-(2"Bromobenzenesulfonyl)-1H-indol-2-yl]-(4-methylpiperazin-1-yl)methanone; [1-(2-Bromobenzenesulfonyl)-3-chloro-1H-indol-2-yl]-(4-methylpiperazin-1- yl)methanone; 1-Benzenesulfonyl-1H-indole-2-carboxylic acid (2"dimethylaminoethyl)-N- methylamide; 1-Benzenesulfonyl-3-bromo-1H-indole-2-carboxylicacid (2-dimethylaminoethyl)-N- methylamide; N-(1-(4-Methylbenzenesulfonyl)-3"bromo-1 H-indole-2-carboxylic acid (2- dimethylaminoethyl)-N-methylamide; 1-(2-Bromo-4-methoxybenzenesulfonyl-1 H-indole-2-carboxylic acid (2- dimethylaminoethyl)-N-methylamide; 1-(2-Bromo-4-methoxyben2enesulfonyl-3-bromo-1 H-indole-2-carboxylic acid (2- dimethylaminoethyl)-N-methylamide; (1-Benzenesulfonyl-5-methoxy-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)-methanone; (1"(4'-Fluoro - benzenesulfonyl-5-methyl-1 H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-(4*-trifluoromethyl)benzenesulfonyl-5-methoxy-1H-indole-2-yl)-(4- Methylpip6razine-1-yl)-methanone; (1-(3'-trifluoromethyl)benzenesulfonyl-5-methyl-1H-indole-2-yl)-(4-Methylpiperazine- 1-yl)-methanone; (1-(Benzenesulfonyl-5-ethoxy-1H"indole-2-yl)-(4-Methylpiperazine-1-yl)-methanone; (1-(4'-lsopropylbenzenesulfonyl-5-ethoxy-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-Benzenesulfonyl-5-thiomethyl-1H-indoIe-2-yl)-(4"Methylpiperazine-1-yl)- methanone; (1-(4'-Fluorobenzenesulfonyl-5-thiomethyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-(4'-lsopropylbenzenesulfonyl-5-thiomethyl-1H-indole-2-yl)-(4-Methylpiperazine-1- yl)-methanone; (1-(3'-trifluoromethyl)benzenesulfonyl-5-thiomethyl"1H-indole-2"yl)-(4" Methylpiperazine-1 -yl)-methanone; 5-methoxy -l-(Benzenesulfonyl) -2- (4-Methylpiperazine"1-yl)-methyl)-1H-indole; 5-methoxy -1-(4'-Bromobenzenesulfonyl) -2- (4-Metliylpiperazine-1-yl)-methyl)"1H- indole; 5"methoxy-1-(3'-Trifluoro methylbenzenesulfonyl)-2-(4-methylpipera2ine"1-yl)- methyl)-1H-indole; (1-(4'-Bromo-benzenesulfonyl-5"methyl-1H-indole"2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-(4'-Bromobenzenesulfonyl-5-methoxyl-1H-indole-2-yl)"(4-Methylpiperazine-1-yl)- methanone; (1-(4'-Fluoro-benzenesulfonyl-5"methoxyl-1H-indole-2-yl)-(4-Methylpiperazine-1-y^^ methanone; 3-Chloro-5-methoxy-1-(2'-bromobenzenesulfonyl)-2-yl-(4-methylpiperazine-1-yl methyl )-1H-indole; (1-(4'-Methoxy)benzenesulfonyl-5-methyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-(3'-Trifluoromethyl)benzenesulfonyl-5-isopropyl-1H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone; (1-(4'-lsopropyl)benzenesulfonyl-5HSopropyl-1H-indole-2-yl)-(4-Methylpiperazine-1- yl)"methanone; (1-Benzenesulfonyl-5-isopropyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)-methanon (1-(4'-Fluoro)benzenesulfonyl-5-isopropyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-Benzenesulfonyl-67-dimethyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; 1-Benzenesulfonyl-5-ethyl-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(4-Fluorobenzenesulfonyl)-5-ethyl-2-(4-methylpiperazin-1-ylmethyl)-1H-indol^ 1-(4-lsopropylbenzenesulfonyl)-5-ethyl-2-(4-methylpiperazin-1-ylmethyl)-1H-indol^ 1-(4-Methoxybenzenesulfonyl)-5-ethyl-2-(4-methylpiperazin-1-ylmethyI)-1HH 1-(2-Bromo-4-methoxybenzenesulfonyl)-5-ethyl-2-(4-methylpiperazin-1-ylmethyl)-1H- indole; 1-Benzenesulfonyl-5-isopropoxy-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(4-Fluorobenzenesulfonyl)-5- isopropoxy -2-(4-methylpiperazin-1-ylmethyl)-1 H- indole; 1-(4-lsopropylbenzenesulfonyl)"5- isopropoxy -2-(4"methylpiperazin-1-ylmethyl)-1 H- indole; 1-(4-Methoxybenzenesulfonyl)-5- isopropoxy -2-(4-methylpiperazin-1-ylmethyl)-1 H- indole; 1-(2-Bromo-4-methoxybenzenesulfonyl)-5- isopropoxy-2-(4-methylpiperazin-1- ylmethyl)-1H-indole; 1-Benzenesulfonyl-5-ethylthio-2-(4-methylpiperazin-1-yImethyl)-1H-indole; 1-(4-Fluorobenzenesulfonyl)-5- ethylthio -2-(4-methylpiperazin-1-ylmethyl)-1 H-indole; 1-(4-lsopropylbenzenesulfonyl)-5- ethylthio -2-(4-methylpiperazin-1-ylmethyl)-1 H- indole; 1-(4-Methoxybenzenesulfonyl)-5- ethylthio -2-(4-methylpiperazin-1-ylmethyl)-1 H- indole; 1-(2-Bromo-4-methoxybenzenesulfonyl)-5- ethylthio-2-(4-methylpiperazin-1- ylmethyl)-1 H-indole; 1-Benzenesulfonyl-5-benzyloxy-2-(4-methylpiperazin-1-ylmethyl)-1 H-indole; 1-(4-Fluorobenzenesulfonyl)-5-benzyloxy-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(4-lsopropylbenzenesulfonyl)-5- benzyloxy -2-(4-methylpiperazin-1-ylmethyl)-1 H- indole; 1-(4-Methoxybenzenesulfonyl)-5- benzyloxy -2-(4-methylpiperazin-1-ylmethyl)-1 H- indole; 1-(2-Bromo-4-methoxybenzenesulfonyl)-5- benzyloxy-2-(4-methylpiperazin-1- ylmethyl)-1H-indole; 1-Benzenesulfonyl-5-cyclopentyloxy-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(4-Fluorobenzenesulfonyl)-5-cyclopentyloxy-2-(4-methylpiperazin-1-ylmethyl)-1H- indole; 1-(4-lsopropylbenzenesulfonyl)-5-cyclopentyloxy-2-(4-methylpiperazin-1-ylmethyl)- 1H-indole; 1-(4-Methoxybenzenesulfonyl)-5-cyclopentyloxy-2-(4-methylpiperazin-1-ylmethyl)- 1H-indole; 1-(2-Bromobenzenesulfonyl)-5- cyclopentyloxy -2-(4-methylpiperazin-1-ylmethyl)-1 H- indole; 1-Benzenesulfonyl-3-bromo-5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(4-Fluorobenzenesulfonyl)-3-bromo-5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)-1H- indole; 1--(4-lsopropylbenzenesulfonyl)-3-bromo-5-ethoxy--2-(4-methylpiperazin-1-ylmethyl)- 1H-indole; 1-(4-Methoxybenzenesulfonyl)-3-bromo-5-ethoxy-2-(4-rnethylpiperazin-1-ylmethyl)- 1H-indole; 1-(2-Bromobenzenesulfonyl)- 3-bromo-5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)-1H- indole; 1-Benzenesulfonyl-3-chloro-5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(4-Fluorobenzenesulfonyl)-3-chloro-5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)- 1H-indole; 1-(4-lsopropylbenzenesulfonyl)-3-chloro-5-ethoxy--2-(4-methylpiperazin-1-ylmethyl)- 1H-indole; 1-(4-Methoxybenzenesulfonyl)-3-chloro-5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)- 1 H-indole; 1-(2-Bromobenzenesulfonyl)- 3- chloro -5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)- 1 H-indole; (1-(4'-Bromo-benzenesulfonyl-5-ethyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-(2'-Bromo-benzenesulfonyl-5-ethyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl^ methanone; (1-(4'-trifluoromethylbenzenesulfonyl-5-ethyl-1H-indole-2-yl)-(4-Met^ yl)-methanone; (1-(4'-trifluoromethylbenzenesulfonyl-5-ethoxyl-1H-indole-2-yl)-(4-Methylpipera2ine-1-yl)-methanone; and (1-(4'-fluorobenzenesulfonyl-5-ethoxyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)-methanone; or a stereoisomer, or a polymorph, or any suitable combination of above such as a nitrogen oxide thereof; a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodnjg; or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug or the pharmaceutically acceptable salt. The present invention also relates to the numerous processes for preparing the compounds of general formula (I) their stereoisomers, their radioisotopes, their N-oxides, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, their useful bio-active metabolites and also includes any suitable combination of the above. In the case of the compounds of general formula (I) where tautomerism may exist, the present invention relates to all of the possible tautomeric forms and the possible mixture thereof. The present invention also relates to the stereoisomers, which as a rule are obtained as racemates that can be separated into the optically active isomers in a manner known per se. The present invention also relates to radio-labeled Isotopes, which are identical to those defined in the general formula (I) but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number found usually in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, iodine, bromine and mTecnitium, exemplified by ^H, ^H, ^^C, ^^C, ^^C, 'N, ^'N, ^'O, 'F, '"^Tc, 'V, S, ^^^1 and ^^^1. Those compounds of general formula (I) as described earlier containing the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. In the case of the compounds of general formula (I) containing geometric isomerism the present invention relates to all of these geometric isomers. The term "nitrogen oxide" or "N-oxide" refers to the oxidation of at least one of the two nitrogens in the compounds of general formula (I), (e.g., mono- or di-oxide). The nitrogen mono-oxides may exist as a single positional isomer, a mixture of 2 positional isomers or oxide of aromatic nitrogen. Suitable pharmaceutically acceptable acid addition salts of compounds of the general formula (I) can be prepared of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, includes, salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benezenesulfonate, p-tolunesulfonate, palmoate and oxalate. Pharmaceutically acceptable salts forming part of this invention are intended to define but not limited to the above list. Suitable pharmaceutically acceptable base addition salts of compounds of the general formula (I) can be prepared of the aforementioned acid compounds of this invention are those which form non-toxic base addition salts, includes, salts containing pharmaceutically acceptable cations, such as Lithium, sodium, potassium, calcium and magnesium, salts of organic bases such as lysine, arginine, guanidine, diethanolamine, choline, tromethamine and the like; ammonium or substituted ammonium salts. Pharmaceutically acceptable salts forming part of this invention are intended to define but not limited to the above list. In addition, pharmaceutically acceptable salts of the compound of general formula (I) can be obtained by converting derivatives which have tertiary amino groups into the corresponding quarternary ammonium salts in the methods known in the literature by using quarternizing agents. Possible quarternizing agents are, for example, alkyl halides such as methyl iodide, ethyl bromide and n-propyl chloride, including arylalkyi halides such as benzyl chloride or 2-phenylethyl bromide. In the addition to pharmaceutically acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of the compounds, in the preparation of other salts, or in the identification and characterization of the compounds or intermediates. The pharmaceutically acceptable salts of compounds of formula (I) may exist as solvates, such as with water, methanol, ethanol, dimethylformamide, ethyl acetate, and the like. Mixtures of such solvates can also be prepared. The source of such solvate can be from the solvent of crystallization, inherent in the solvent preparation or crystallization, or adventitious to such solvent. Such solvates are within the scope of this invention. The invention also encompasses the pharmaceutically acceptable prodrugs of the compounds of general formula (I). A prodrug is a drug which has been chemically modified and may be biologically in-active at the site of action, but which may be degraded or modified by one or more enzymatic or other in-vivo processes to the parent form. This prodaig should have a different pharmacokinetic profile than the parent, enabling easier absorption across the mucosal epithelium, better salt formation, or solubility, and/or improved systemic stability (an increase in the plasma half-life, for example). Typically, such chemical modifications include any-one of the following: 1. ester or amide derivatives which may be cleaved by esterases or lipases; 2. peptides which may be recognized by specific or non-specific proteases; 3. N-glycosyl or 0-glycosyl derivatives; 4. derivatives that accumulate at a site of action through membrane selection of a prodrug form or a modified prodrug form; or 5. any combination of 1 to 4, above. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in H. Bundgard, Design of prodrugs, (1985). Another aspect of the present invention comprises of a pharmaceutical composition, containing at least one of the compounds of general formula (I), their derivatives, their analogs, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates thereof as an active ingredient, together with pharmaceutically employed carriers, auxiliaries and the like. An effective amount of a compound of general formula (I), or their salt can be used to produce a medicament, along with conventional phannaceuticai auxiliaries, carriers and additives. The present invention also relates to the pharmaceutically acceptable compositions containing them, and the use of these compounds and compositions in medicine. The present invention provides the compounds of general formula (I), to prepare the medicaments useful in the treatment and/ or prophylaxis of certain disorders such as psychosis, paraphrenia, anxiety, depression, mania, schizophrenia, schizophreniform disorders, migraine headache, drug addiction, convulsive disorders, personality disorders, hypertension, autism, post-traumatic stress syndrome, alcoholism, panic attacks, obsessive-compulsive disorders, chronobiological abnormalities and circadian rhythms, cognitive memory disorders e.g. Alzheimer's disease and age-related cognitive decline, ADHD (Attention Deficient Disorder/ Hyperactivity Syndrome), amylotrophic lateral sclerosis, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, panic attacks, and also disorders associated with spinal trauma and / or head injury such as hydrocephalus. Other conditions where there are low endogenous melatonin levels benefits may be obtained in cases of osteoporosis, ischemic stroke, SIDS in young infants, reproduction, glaucoma and sleep disorders. Compounds of this invention are expected to be of use in the treatment of mild cognitive impairment and other neurodegenerative disorders like Alzheimer's disease. Parkinsonism and Huntington's chorea. The compounds of this invention could be of use in the treatment of certain Gl (Gastrointestinal) disorders such as IBS (Irritable bowel syndrome) or chemotherapy induced emesis. Also these compounds can help in modulation of eating behavior and thereby reduce morbidity and mortality associated with the excess weight. The present invention provides a method for the treatment of a human or a animal subject suffering from disorders such as, anxiety, depression, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders e.g. Alzheimer's disease and age-related cognitive decline, ADHD (Attention Deficient Hyperactivity Disorder), personality disorders, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, panic attacks, chronobiological abnormalities, circadian rhythms, anxiolytic, osteoporosis, ischemic stroke, lower the risk of SIDS in young infants with low endogenous melatonin levels, reproduction, glaucoma, sleep disorders (including disturbances of Circadian rhythm) and also disorders associated with spinal trauma and /or head injury such as hydrocephalus. Compounds of the invention are further expected to be of use in the treatment of mild cognitive impairment and other neurodegenerative disorders like Alzheimer's disease. Parkinsonism and Huntington's chorea. Compounds of the present invention may be administered in combination with other pharmaceutical agents, such as apo-B/MTP inhibitors, MCR-4 agonists, CCK-A agonists, monoamine reuptake inhibitors, sympathomimetic agents, adrenergic receptor agonists, dopamine agonists, melanocyte-stimulating hormone receptor analogs, cannabinoid 1 receptor antagonists, melanin concentrating hormone agents, dehydroepiandrosterone or analogs thereof, glucocorticoid receptor agonists or antagonists, orexin receptor antagonists, urocortin binding protein antagonists, glucagon-like peptide-1 receptor agonists, ciliary neurotrophic factors, AGRPs (human agouti-related proteins), ghrelin receptor antagonists, histamine 3 receptor antagonists or reverse agonists, neuromedin U receptor agonists, and the like, in a therapeutically effective amount via a suitable pharmaceutical composition, to achieve the desired effect in mammals as well as humans. The phrase "pharmaceutically acceptable" indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith. The terms "treating", "treat", or "treatment" embrace all the meanings such as preventative, prophylactic and palliative. The term "compounds of the present invention" (unless specifically identified otherwise) refer to compounds of Formulae (I), nitrogen oxides thereof, prodnjgs of the compounds or nitrogen oxides, pharmaceutically acceptable salts of the compounds, nitrogen oxides, and/or prodrugs, and hydrates or solvates of the compounds, nitrogen oxides, salts, is and/or prodrugs, as well as, all stereoisomers (including diastereoisomers and enantiomers), tautomers and isotopically labeled compounds. Detailed description of the invention: The present invention relates to compounds of general formula (I), are described in the summary above. Suitable groups represented by Ri, R2, R3, R4, R5, Re, R7. Rs, R9, R10, R11, R12, Ri3, Ri4, Ri5, R16 and R17, wherever applicable, may be selected be from the following group: halogen atom such as fluorine, chlorine, bromine or iodine; perhaloalkyi particularly perhalo (CrC6)alkyl such as fluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyi, fluoroethyl, difluoroethyl and the like; perhaloalkoxy particularly perhalo(CrC6)alkoxy such as fluoromethoxy, difluoromethoxy, trifluoromethoxy and the like; substituted or unsubstituted (Ci-Ci2)alkyl group, especially, linear or branched (Ci-C8)alkyl group, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, hexyl, iso-hexyl, heptyl, octyl and the like; substituted or unsubstituted (C2-Ci2)alkenyl group such as ethylene, n-propylene pentenyl, hexenyl, heptynyl, heptadienyl and the like; (C2-Ci2)alkynyl substituted or unsubstituted (C2-Ci2)alkynyl group such as acetylene and the like; cyclo(C3-C7)alkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cydoheptyl, the cycloalkyi group may be substituted; cyclo(C3-C7)alkenyl group such as cyclopentenyl, cyclohexenyl, cycloheptynyl, cycloheptadienyl, cycloheptatrienyl and the like, the cycloalkenyl group may be substituted; (CrCi2)alkoxy, especially, (CrC6)alkoxy group such as methoxy, ethoxy, propyloxy, butyloxy, iso-propyloxy and the like, NA/hich may be substituted; cycloCCa-Cy) alkoxy group such as cyclopropyioxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy and the like, the cycloalkoxy group may be substituted; aryl group such as phenyl or naphthyl, the aryl group may be substituted; aralkyi group such as benzyl, phenethyl, C6H5CH2CH2CH2, naphthylmethyl and the like, the aralkyi group may be substituted and the substituted aralkyi is a group such as CH3C6H4CH2, Hal-C6H4CH2, CH3OC6H4CH2, CH3OC6H4CH2CH2 and the like; aralkoxy group such as benzyloxy, phenethyloxy, naphthylmethyloxy, phenylpropyloxy and the like, the aralkoxy group may be substituted; heterocyclyl groups such as aziridinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl and the like, the heterocyclyl group may be isubstituted; heteroaryl group such as pyridyl with the exception of 2-pyridyl and 4-pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, imidazolyl, oxadiazolyl, tetrazolyl, benzopyranyl, benzofuranyl and the like, the heteroaryl group may be substituted; heterocyclo(Ci-C6)alkyl, such as pyrrolidinylalkyl, piperidinylalkyi, morpholinylalkyi, thiomorpholinylalkyi, oxazolinylalkyi and the like, the heterocyclo(Ci-C6)alkyl group may be substituted; heteroaralkyi group such as furanylmethyl, pyridinylmethyl, oxazolylmethyl, oxazolylethyl and the like, the heteroaralkyi group may be substituted; heteroaryloxy, heteroaralkoxy, heterocycloalkoxy, wherein heteroaryl, heteroaralkyi, heterocycloalkyi and heterocyclylalkyi moieties are as defined earlier and may be substituted, such as furan-2-ylmethoxy-; acyl groups such as acetyl, propionyl or benzoyl, the acyl group may be substituted; acyloxy group such as CH3COO, CH3CH2COO, CeHsCOO and the like which may optionally be substituted, acylamino group such as CH3CONH. CH3CH2CONH, C3H7CONH, CeHgCONH which may be substituted, (CrC6)monoalkylamino group such as CH3NH, C2H5NH, C3H7NH, C6H13NH and the like, which may be substituted, (CrC6)dialkylamino group such as N(CH3)2, CH3(C2H5)N and the like, which may be substituted; arylamino group such as CeHsNH, CH3(C6H5)N, C6H4(CH3)NH, NH-C6H4-Hal and the like, which may be substituted; arylalkylamino group such as C6H5CH2NH, C6H5CH2CH2NH, C6H5CH2NCH3 and the like, which may be substituted; hydroxy(CrC6)alkyl which may be substituted, amino(Ci-C6)alkyl which may be substituted; mono(Cr C6)alkylamino(Ci-C6)alkyl, di(Ci-C6)alkylamino(CrC6)alkyl group which may be substituted, alkoxyalkyl group such as methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like, which may be substituted; aryloxyalkyi group such as C6H5OCH2, C6H5OCH2CH2, naphthyloxymetnyi ana ine IIKS, wmun may uc substituted; aralkoxyalkyl group such as C6H5CH2OCH2, C6H5CH2OCH2CH2 and the like, which may be substituted; (Ci-C6)alkylthio, thio(Ci-C6)alkyl which may be substituted, alkoxycarbonylamino group such as C2H5OCONH, CH3OCONH and the like which may be substituted; aryloxycarbonylamino group as CeHsOCONH, C6H5OCONCH3, C6H5OCONC2H5, C6H4CH3OCONH, C6H4(OCH3)OCONH and the like which may be substituted; aralkoxycarbonylamino group such C6H5CH2OCONH, C6HSCH2CH2OCONH. C6H5CH20CON(CH3). C6H5CH20CON(C2H5). C6H4CH3CH2OCONH, C6H4OCH3CH2OCONH and the like, which may be substituted; aminocarbonylamino group; (CrC6)alkylaminocarbonylamino group, di(Cr C6)alkylaminocarbonylamino group; (CrC6)alkylamidino group, (Cr C6)alkylguanidino, di(Ci-C6)alkylguanidino groups, hydrazine and hydroxylamino groups; carboxylic acid or its derivatives such as amides, like CONH2, alkylaminocarbonyl like CH3NHCO, (CH3)2NCO, C2H5NHCO, (C2H5)2NCO, arylaminocarbonyl like PhNHCO, NapthylNHCO and the like, araikyiaminocarbonyl such as PhCH2NHC0, PhCH2CH2NHCO and the like, heteroarylaminocarbonyl and heteroaralkylamino carbonyl groups where the heteroaryl groups are as defined earlier, heterocyclylaminocarbonyl where the heterocyclyl group is as defined earlier, carboxylic acid derivatives such as esters, wherein the ester moieties are alkoxycarbonyl groups such as unsubstituted or substituted phenoxycarbonyl, naphthyloxycarbonyl and the like; aralkoxycarbonyl group such as benzyloxycarbonyl, phenethyloxycarbonyl, naphthyimethoxycarbonyj and the like, heteroaryloxycarbonyl, heteroaralkoxycarbonyl, wherein the heteroaryl group is as defined earlier, heterocycloxycarbonyl where heterocycle is as defined earlier and these carboxylic acid derivatives may be substituted; sulfonic acid or its derivatives such as SO2NH2, SO2NHCH3, S02N(CH3)2, SO2NHCF3, S02NHCO(Ci-C6)alkyl, S02NHC0aryl where the aryl group is as defined earlier and the sulfonic acid derivatives may be substituted; phosphoric acid and its derivatives as P(0)(0H)2, P(0)(OCi-C6-alkyl)2, P(0)(0-aryl)2 and the like. Suitable cyclic structures formed by the two adjacent groups, such as Ri and R2 or R2 and R3 or R4 and R5 or R5 and Re or Re and R7 or R7 and Rs or Rs and Rg; optionally R13 along with either R16 or R17 and the two nitrogen atoms may form a 5-, 6- or 7- membered heterocyclic ring, which may be further substituted with R14 and Ri5, and may have either one, two or three double bonds; optionally R12 and Rie or Ri4 and Rie together with carbon atoms to which they are attached may contain either 4, 5 or 6 ring atoms, which optionally contains one or more heteroatoms, selected from the group containing oxygen, nitrogen or sulfur, and/or one or more double bonds and other possible combinations such as both double bond and hetero atoms. An example, of suitable stmctures thus formed at the 2-position of indole nucleus includes, an optionally substituted piperazinyl, imidazolyl, pyrimidinyl, pyrazinyl, N,N,N\NMetraalkyldiaminoalkane, N,N,N\N'-tetraalkyldiaminoalkene, N-aryl,N,N',N'-trialkyldiaminoalkane, N-arylcarbonyl,N,N',N'"trialkyldiaminoalkane, N-arylthiocarbonyl,N,N',N'-trialkyldiaminoalkane and the like. Suitable substituents on these include hydroxy, halogen atom such as chlorine, bromine and iodine; nitro, cyano, amino, formyl, (CrC3)alkyl, (CrC3)alkoxy, thioalkyi, alkylthio, phenyl or benzyl groups. Compounds of the present invention may be synthesized by synthetic routes that include processes analogous to those known in the chemical arts, particularly in light of the description contained herein. The starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wl) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-1 9, Wiley, New York (1 967-1999 ed.), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)). For illustrative purposes, the reaction schemes depicted below provide potential routes for synthesizing the compounds of the present invention as well as key intermediates. For a more detailed description of the individual reaction steps, see the Examples section. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the inventive compounds. Although specific starting materials and reagents are depicted in the schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions. In addition, many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art. In certain circumstances there may also be a need to protect hydroxy groups and amino groups during the synthetic processes of the present invention. Those skilled in the art are familiar with such "hydroxy protecting groups" and such "amino protecting groups." For a general description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991. One skilled in the art readily determines the need for such protection. The selection of protecting group employed is not critical so long as the derivatized group is stable to the condition of subsequent reaction(s) and can be removed at the appropriate point without disrupting th'" -—'^j-^^^^r ,^f th^ mi^iam iio Suitable amino-protecting groups (NH-Pg) include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyioxycarbonyl (CBz) and Fluorenylmethyleneoxycarbonyl (Fmoc). Preferred indole -NH protecting groups are trimethylsilylethoxymethyl, benzyl, tosyl, carbamate, amide, alkyl oraryl sulfonamide, while maleimide protecting groups include alkoxy, benzyl, dialkoxybenzyl, benzyloxyalkyi or allyl. Preferred hydroxy protecting groups are ether or ester derivatives of the hydroxy group such as tert-butyldiphenylsilyloxy (TBDPS), tert-butyldimethylsilyloxy (TBDMS), triphenylmethyl (trityl), mono- or di- methoxytrityl, or an alkyl or aryl ester. The present invention also provides processes for preparing compounds of general formula (I), as defined above their stereoisomers, their polymorphs, their phannaceutically acceptable salts, their pharmaceutically acceptable solvates and novel intermediates involved therein, which are as described below. In the following description and reaction schemes Ri, R2, R3, R4, Rs, Re, R7, Ra, R9, R10, R11, R12, Ri3, Ri4, Ri5, R16, Ri7, Q, A and n are as defined previously for the compounds of general formula (I) and R is as defined elsewhere in the specification. Compounds of general formula (I) can be prepared by any of the methods described below. Reference includes PCT application WO 99/09025, which has incorporated herein by reference. The present invention also provides processes for preparing compounds of general formula (I) as defined above, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their geometric forms, their N-oxides, their polymorphs, their isotopically-labeled derivatives, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and novel intermediates involved therein, which are as described below: Scheme -1 : Compounds of general formula (I), may be prepared by reacting a compound of formula (II) given below, where Ri, R2, R3, R4, Rio and A are as defined in relation to formula (I) , X is halogeno, for example, a chloro, bromo or iodo; R represents either of a suitable N-protecting group such as acetyl, triflouroacetyl, trityl, t-butyloxycarbonyl (t-BOC) or a group such as. where R5, Re, R7. Rs and R9 are as defined earlier; with a compound of formula (III) or its acid addition salt, where R13, R14, R15, Rieand R^are as defined in relation to compound of formula (I) or precursor thereof; and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (1); and/or ii) removing any protecting groups; and/or iii) forming a pharmaceutically acceptable salt or prodaig thereof. Preferably the substituents selected for the compounds of formulae (II) and (III) are either inert to the reaction conditions or the sensitive groups are protected using suitable protecting groups. Whenever R is a suitable protecting group, an additional step as described in Scheme 2 is required to prepare compounds of formula (I). The above reaction is preferably carried out in a solvent such as THF, acetone, DMF, xylene, toluene, methanol, ethanol, propanol and the like and preferably using either acetone or DMF. The inert atmosphere may be maintained by using inert gases such as N2, Ar or He. The reaction mixture is generally heated to an elevated temperature or reflux temperature of the solvent, until the reaction is complete. A wide variety of acid-acceptor agents can be used in this condensation. However, preferred basic agents are sodium carbonate, sodium bicarbonate, potassium carbonate, sodium acetate, sodium alkoxides and the like, with a preferred basic agent being K2CO3. Reaction times of about 30 minutes to 72 hours are common. At the end of reaction, the volatile components are removed under reduced pressure. The reaction mixture can be optionally acidified before work-up. The product can be isolated by precipitation, washed, dried and further purified by standard methods such as recrystallization, column chromatography etc. Optional steps (i), (ii) and (iii) can be carried out using conventional methods. These will depend upon the precise nature of the substituents on the indole in each case. Examples of suitable reactions are illustrated hereinafter. Compounds represented by the general formula (II) are prepared by the method described elsewhere in the specification. Compounds of formula (III) are commercially available, or they may be prepared by conventional methods or by modification, using known processes, of commercially available compounds of formula (III). Scheme - 2 : Alternatively, compounds of formula (I) may be prepared by reacting a compound of formula (IV) given below, wherein A, Ri, R2, R3, R4, R10, R13, Ri4, R15, Rieand Riyare as defined in relation to formula (I); with any one of the following compound represented by general formula (V), where R5, Re, R7. Rs and Rg, are as defined in relation to formula (I) and X is a halogeno, preferably chloro or bromo; and thereafter if desired or necessary carrying out steps (i), (ii) and/or (iii) as described above. Preferably the substituents selected for the compounds of formula (IV) and (V) are either not affected by the reaction conditions or else the sensitive groups are protected using suitable groups. Compounds of formula (IV) and (V) are suitably reacted together in an inert organic solvent which includes, aromatic hydrocarbons such as toluene, o-, m-, p-xylene; halogenated hydrocarbons such as methylene chloride, chloroform, and chlorobenzene; ethers such as diethylether, diisopropyl ether, tert-butyl methyl ether, dioxane, anisole. and tetrahydrofuran; nitriles such as acetonitrile and propionitrile; ketones such as acetone, methyl ethyl ketone, diethyl ketone and tert-butyl methyl ketone; alcohols such as methanol, ethanol, n-propranol, n-butanol, tert-butanol and also DMF (N.N-dimethylformamide), DMSO (dimethyl sulfoxide) and water. The preferred list of solvents includes DMSO, DMF, acetonitrile and THF. Mixtures of these in varying ratios can also be used. Suitable bases are, generally, inorganic compounds such as alkali metal hydroxides and alkaline earth metal hydroxides, such as lithium hydroxide, sodium hydroxide, potassium hydroxide and calcium hydroxide; alkali metal oxides and alkaline earth metal oxides, lithium oxide, sodium oxide, magnesium oxide and calcium oxide; alkali metal hydrides and alkaline earth metal hydrides such as lithium hydride, sodium hydride, potassium hydride and calcium hydride; alkali metal amides and alkaline earth metal amides such as lithium amide, sodium amide, potassium amide and calcium amide; alkali metal carbonates and alkaline earth metal carbonates such as lithium carbonate and calcium carbonate; and also alkali metal hydrogen carbonates and alkaline earth metal hydrogen carbonates such as sodium hydrogen carbonate; organometallic compounds, particularly alkali-metal alkyls such as methyl lithium, butyl lithium, phenyl lithium; alkyl magnesium halides such as methyl magnesium chloride and alkali metal alkoxides and alkaline earth metal alkoxides such as sodium methoxide, sodium ethoxide, potassium ethoxide, potassium tert-butoxide and di-methoxymagnesium, further more organic bases e.g. triethylamine, triisopropylamine, and N-methylpiperidine, pyridine. Sodium hydroxide, Sodium methoxide. Sodium ethoxide, potassium hydroxide potassium carbonate and triethylamine are especially preferred. Suitably the reaction may be effected in the presence of phase transfer catalyst such as tetra-n-butylammonium hydrogen sulphate and the like. The inert atmosphere may be maintained by using inert gases such as N2, Ar or He. Reaction times may vary from 1 to 24 hrs, preferably from 2 to 6 hours, whereafter, if desired, the resulting compound is continued into a salt thereof. Compounds of formula (V) are commercially available, or they may be prepared by conventional methods or by modification, using known processes, of commercially available compounds of formula (V). Scheme - 3 : Compounds of general formula (I) may be prepared by reacting a compound of formula (VI) given below, where Ri, R2, R3, R4, and Rio are as defined in relation to formula (I), R represents either of a suitable N-protecting group such as acetyl, triflouroacetyl, or a group such as, where R5, Re, R7, Rs and Rgare as defined earlier; with a compound of formula (III) or its acid addition salt, where R13, R14, R15, Rieand Riyare as defined in relation to compound of formula (I) or precursor thereof; by standard peptide coupling for example using bis(2-oxo-3-oxazolidinyl) phosphoric chloride (BOP-CI) and thereafter if desired or necessary carrying out steps (i), (ii) and/or (iii) as described above. Scheme -4 : In this method N,N'-thionyl-diimidazole is first prepared by reacting imidazole with thionyl chloride. The former is then reacted with the compound of formula (VI) N-(substituted indolyl)alkanoic acid and the resulting N-(substituted indolyl-alkanoyl)imidazole is reacted with N-substituted amine compound of formula (III). If desired the N,N'-thionyl-diimidazole and N-(substituted indolylalkanoyl)imidazole intermediates can be isolated prior to the next reaction in the succeeding step, but it is advantageous to carry out the entire sequence of steps upto fomnation of N-(substituted indolyl-alkanoyl)-4-substituted-amine in essentially one operation, that is by reacting each intermediate without isolation with the next succeeding reactant using the same solvent medium for the entire sequence of reactions. Suitable solvents are organic solvents inert under the conditions of the reactions, for example tetrahydrofuran, diethylether, dibutylether and the like. The reactions are preferably conducted at a temperature in the range from about -10 °C to about 50 °C. Amide intermediates can be reduced to the desired compound of formula (I), wherein A = -CH2-, by the use of reducing agents capable of converting the amido functionality to an amino moiety. Such agents are, for example, lithium aluminum hydride or other complex aluminum hydrides. The reducing reactions are, performed in diethyl ether or tetrahydrofuran, or in a stable diborane complex such as boran- tetrahydrofuran or borane-dimethylsulphide or others (J. Org. Chem. 1982, 47, 1389) used in an appropriate solvent (e.g. tetrahydrofuran). Many other useful reducing agents are l wherein Ri, R2, R3, R4 and Rio are as defined in relation to formula (I), X is a halogeno, for example a chloro, bromo or iodo; while R represents either of a suitable N-protecting group such as acetyl, triflouroacetyl, benzyl, trityl, t-butyloxycarbonyl (t-BOC) or a group such as, where R5, Re, R7. Rs and Rg are as defined earlier, with a compound of formula (III) or its acid addition salt, where R13, R14, R15. Rieand Ri/are as defined in relation to compound of formula (I) or precursor thereof; in suitable anhydrous solvent; and thereafter if desired or necessary carrying out steps (i), (ii) and/or (iii) as described above. The reaction is preferably carried out at a temperature in the range from about -5 ""C to about 65 °C, in the presence of acid acceptor in an organic solvent inert under the conditions of the reactions, for example tetrahydrofuran, diethylether, ethylene chloride and the like. The purpose of acid acceptor is to take up the hydrogen halide which is split out during the course of the reaction and includes sodium carbonate, sodium bicarbonate, potassium carbonate, sodium acetate, sodium alkoxides and the like. The acid acceptor can also be in the form of an excess quantity of substituted amine. Scheme - 6 : Alternatively, the compounds of formula (I) where A = -CH2, can be obtained by carrying out chemical, catalytic or enzymatic reduction of the compounds of formula (I) where A = -C=0 using the known procedures. During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, Ed J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. For example, suitable protecting groups for the piperazine group include BOG, -COCCI3, "COCF3. The protecting groups may be removed according to the standard procedures. The protecting groups may be removed at a convenient subsequent stage using methods known from the art. Certain amines, such as N-substituted piperazines, can be prepared by acylation or alkylation of the appropriate NH-piperazine compound according to the standard procedures. The compounds of the present invention may contain one or more asymmetric centers and therefore they also exist as stereoisomers. The ■ stereoisomers of the compounds of the present invention may be prepared by one or more ways presented below: i) One or more of the reagents may be used in their optically active form, ii) Optically pure catalyst or chiral ligands along with metal catalyst may be employed in the reduction process. The metal catalyst may be Rhodium, Ruthenium, Indium and the like. The chiral ligands may preferably be chiral phosphines (Principles of Asymmetric synthesis, J. E. Baldwin Ed., Tetrahedron series, 14, 311-316). iii) The mixture of stereoisomers may be resolved by conventional methods such as forming a diastereomeric salts with chiral acids or chiral amines, or chiral amino alcohols, chiral amino acids. The resulting mixture of diastereomers may then be separated by methods such as fractional crystallization, chromatography and the like, which is followed by an additional step of isolating the optically active product by hydrolyzing the derivative (Jacques et. al., "Enantiomers, Racemates and Resolution", Wiley Interscience, 1981). iv) The mixture of stereoisomers may be resolved by conventional methods such as microbial resolution, resolving the diastereomeric salts formed with chiral acids or chiral bases. Chiral acids that can be employed may be tartaric acid, mandelic acid, lactic acid, camphorsulfonic acid, amino acids and the like. Chiral bases that can be employed may be cinchona alkaloids, brucine or a basic amino acid such as lysine, arginine and the like. The pharmaceutically acceptable salts forming a part of this invention may be prepared by treating the compound of formula (I) with 1-6 equivalents of a base such as Lithium, ammonia, substituted ammonia, sodium hydride, sodium methoxide, sodium ethoxide, sodium hydroxide, potassium t-butoxide, calcium hydroxide, calcium acetate, calcium chloride, magnesium hydroxide, magnesium chloride and the like. Solvents such as water, acetone, ether, THF, methanol, ethanol, t-butanol, dioxane, isopropanol, isopropyl ether or mixtures thereof may be used. Organic bases such lysine, arginine, methyl benzylamine, ethanolamine, diethanolamine, tromethamine, choline, guanidine and their derivatives may be used. Acid addition salts, wherever applicable may be prepared by treatment with acids such as tartaric acid, mandelic acid, fumaric acid, maleic acid, lactic acid, salicyclic acid, citric acid, ascorbic acid, benzene sulfonic acid, p-toluene sulfonic acid, hydroxynaphthoic acid, methane sulfonic acid, malic acid, acetic acid, benzoic acid, succinic acid, palmitic acid, oxalic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and the like in solvents such as water, alcohols, ethers, ethyl acetate, dioxane, DMF or a lower alkyl ketone such as acetone, or the mixtures thereof. Different polymorphs may be prepared by crystallization of compounds of general formula (I) under different conditions such as different solvents or solvent mixtures in varying proportions for recrystallization, various ways of crystallization such as slow cooling, fast cooling or a very fast cooling or a gradual cooling during crystallization. Different polymorphs may also be obtained by heating the compound, melting the compound and solidification by gradual or fast cooling, heating or melting under vacuum or under inert atmosphere and cooling under either vacuum or inert atmosphere. The various polymorphs may be identified by either one or more of the following techniques such as differential scanning calorimeter, powder X-ray diffraction, IR spectroscopy, solid probe NMR spectroscopy and thermal microscopy. The novel intermediates of formula represented by general formula (IV), which are useful in the preparation of compounds of formula (I), also form the part of this invention. The novel intermediate of general formula (IV) is defined as below. wherein A may be either a -CR11R12", -C=0, -SO2-, -(CO)NH- or -C=S group. Ri, R2, R3, R4, R10, R11, R12. Ri4 and R15 may be same or different and each independently represent hydrogen, halogen, 0x0, thio, perhaloalkyl, hydroxy, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (CrCi2)alkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (C3- C7)cycloalkyl, (C3-C7)cycloalkenyl, bicycloalkyi, bicycloalkenyi, (CrCi2)alkoxy, cyclo(C3-C7)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heterocyclylalkyi, heteroaralkyi, heteroaryloxy, heteroaralkoxy, heterocyclylalkyioxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl, aryioxycarbonyl, aralkoxycarbonyl, heterocyclylaikoxycarbonyl, heteroaryloxycarbonyl, hydroxyalkyi, aminoalkyi, monoalkylaminoalkyi, dialkylaminoalkyi, alkoxyalkyl, aryloxyalkyi, aralkoxyalkyi, alkylthio, thioalkyi, alkoxycarbonylamino, aryloxycarbonylamino, aralkyloxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocailDonylamino, alkylamidino, alkylguanidino, dialkylguanidino, hydrazine, hydroxylamino, carboxylic acid and its derivatives, sulfonic acids and its derivatives, phosphoric acid and its derivatives; or the adjacent groups like Ri and R2 or R2 and R3 or R3 and R4 together with carbon atoms to which they are attached may form a five or a six membered ring, optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms; or R11 and R12 together with the carbon atoms to which they are attached may form a three to six membered ring, optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms. Ri3, R16 and R17 may be same or different and each independently represents hydrogen, substituted or unsubstituted groups selected from linear or branched (Ci-Ci2)alkyl, (C2-Ci2)alkenyl, (C2-Ci2)alkynyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkenyl, bicycloalkyi, bicycloalkenyi, aryl, aralkyl, heteroaryl, heterocyclylalkyi; alternatively Ri3 along with either Rie or R17 and the two nitrogen atoms may form a 5-, 6- or 7-membered heterocyclic ring, which may be further substituted with R14 and R15, and nay have either one, two or three double bonds, with the proviso that, When Ri3 along with Ri6 together with the intervening nitrogens form a piperazine or a substituted piperazine ring, then R17 is never aryl substitutent. "n" is an integer ranging from 1 to 4, wherein the carbon chains which "n" represents may be either linear or branched. Another aspect of the present invention comprises of a pharmaceutical composition, containing at least one of the compounds of the general formula (I), their derivatives, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their geometric forms, their N-oxides, their polymorphs, their isotopically-labeled derivatives, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates thereof as an active ingredient, together with pharmaceutically employed carriers, auxiliaries and the like. The pharmaceutical compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, intranasal, parental (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or a form suitable for administration by inhalation or insufflation. The dose of the active compounds can vary depending on factors such as the route of administration, age and weight of patient, nature and severity of the disease to be treated and similar factors. Therefore, any reference herein to a pharmacologically effective amount of the compounds of general formula (I) refers to the aforementioned factors. For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid). For buccal administration, the composition may take the form of tablets or lozenges formulated in conventional manner. The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of an aerosol spray from a pressurized container or a nebulizer, or from a capsule using a inhaler or insufflator. In the case of a pressurized aerosol, a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas and the dosage unit may be determined by providing a valve to deliver a metered amount. The medicament for pressurized container or nebulizer may contain a solution or suspension of the active compound while for a capsule it preferably should be in the form of powder. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch. A proposed dose of the active compounds of this invention, for either oral, parenteral, nasal or buccal administration, to an average adult human, for the treatment of the conditions referred to above, is 0.1 to 200 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day. Aerosol formulations for treatment of the conditions referred to above (e.g., migraine) in the average adult human are preferably arranged so that each metered dose or "puff' of aerosol contains 20 ^g to 1000 |ig of the compound of the invention. The overall daily dose with an aerosol will be within the range 100 |xg to 10 mg. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time. The affinities of the compound of this invention for the various serotonin receptors are evaluated using standard radioligand binding assays and are described here. Radioligand binding assays for various 5-ht receptor sub-tvpes : International Patent Publication WO 04/000205, WO 04/000845, WO 04/000849, (Suven Lifesciences Limited) gives detailed list of methods used for Radioligand assays and related prior art, all of which is incorporated herein along with the references. The following description illustrates the method of preparation of variously substituted compounds of general formula (I), according to the methods described herein. These are provided by the way of illustration only and therefore should not be constnjed to limit the scope of the invention. Commercial reagents were utilized without further purification. Room temperature refers to 25 - 30 °C. Melting points are uncorrected, IR spectra were taken using KBr and in solid state. Unless otherwise stated, all mass spectra were carried out using ESI conditions. 'H NMR spectra were recorded at 200 or 400 MHz on a Bruker instrument. Deuterated chloroform (99.8 % D) was used as solvent. TMS was used as internal reference standard. Chemical shift values reported herein are expressed in parts per million (8 ppm) values. The following abbreviations are used for the multiplicity for the NMR signals: s=Singlet, bs=broad Singlet, d=doublet, t=triplet, q=quartet, qui=quintet, sep=septate, dd=doublet doublet, dt=doublet triplet, tt=triplet of triplets, m=multiple. NMR, mass were corrected for background peaks. Specific rotations were measured at room temperature using the sodium D (589 nm). Chromatography refers to column chromatography performed using 60-120 mesh silica gel and executed under nitrogen pressure (flash chromatography) conditions. Description 1 : (1H-lndol-2-ylH4-methylpiperazin-1-yl)methanone(D1) 1H-lndole-2-carboxylic acid (3 g, 15.7 mmoles) was stirred with oxalyl chloride (2.25 mL, 25.7 mmoles) in 20 mL dichloromethane at 25 °C. After completion of the reaction (TLC), volatile substances were distilled off under the reduced pressure. The residue was taken in 20 mL dichloroethane, and to this stirred solution, was added N-methylpiperazine (1.1 g, 0.011 moles). The reaction mixture was further stirred for next 3 - 5 hours, till the reaction completes (TLC). Reaction mixture was diluted with dichloromethane 20 mL), washed with water, brine and saturated solution of sodium bicarbonate. The organic layer was dried over sodium sulfate and the organic solvents were evaporated under vacuo. The product was isolated using column chromatography on silica gel G stationary phase and suitable combinations of ethyl acetate and methanol in increasing gradient as the mobile phase. The structure of compound thus obtained was confirmed by IR, NMR and mass spectral analyses. Description 2-18(D2-D18) Using essentially the same procedure described in description 1 hereinabove and employing appropriately substituted indole-2-carboxylic acid with substituted alkyl piperazine or N,N',N'-trimethylethylene-1,2-diamine, compounds given in the list 1 were prepared. The structure of compounds thus obtained were confirmed by IR, NMR and mass spectral analyses. List. 1 Description Mass ion (M+H)* D 1 (1H-lndol-2-yl)-(4-methylpiperazin-1-yl)methanone 244 D 2 (5-Methoxy-1 H-indol-2-yl)-(4-methylpiperazin-1-yl)methanone 274 D 3 (5"Ethoxy-1 HHndol-2-yl)-(4-methylpiperazin-1-yl)methanone 288 0 4 (5-Methylthio-1H-indol-2-yl)-(4-methylpiperazin-1-yl)methanone 290 D 5 (5-Methyl-1 H-indol-2-yl)-(4-methylpiperazin-1-yl)methanone 258 D 6 (5-lsopropyl-1 H-indol"2-yl)-(4-methylpiperazin-1-yl)methanone 286 D 7 (6,7"Dimethyl-1 H-indol-2-yl)-(4-methylpipera2in-1 -yl)methanone 272 D 8 (5,7-Dimethyl-1 H-indol-2-yl)-(4-methylpipera2in-1 -yl)methanone 272 D 9 5-Ethoxy-1H-indol-2-carboxylic acid, N-(N',N'-dimethylaminoethyl)- 290 N-methylamide. D 10 5-Methylthio-1H-indol-2-carboxylicacid, N-(N\N'- 292 dimethylaminoethyl)-N-methylamide. D 11 5-Methyl-1H-indol-2-carboxylicacid, N-(N',N'-dimethylaminoethyl)- 260 N-methylamide. D 12 5"lsopropyl-1H"indol-2-carboxylicacid, N-(N',N'- 288 dimethylaminoethyl)-N-methylamide. D 13 6,7-Dimethyl-1 H-indol-2-carboxylic acid, N-(N\N'- 274 dimethylaminoethyl)-N-methylamide. D 14 5,7-Dimethyl-1H-indol-2-carboxylic acid, N-(N',N'- 274 dimethylaminoethyl)-N-methylamide. D 15 IH-lndole-2-carboxylicacid, N"(N',N'-dimethylaminoethyl)-N- 246 methylamide D 16 3-Chloro-(1H-indol-2-yl)-(4"methylpiperazin"1-yl)methanone 278 D 17 3-ChlorO"(5-methoxy-1H-indol-2-yl)"(4-methylpiperazin-1- 308 yl)methanone D 18 (3-BromO"(1H-indole-2-carboxylicacid)) N-(N',N'- 324 Description 19 : 2-(4-Methylpiperazin-1-ylmethyl)--1H-indole (D19) (1H-lndol-2-yl)-(4-methylpiperazin-1-yl)methanone (2.44 g, 0.01 moles) in THF was treated with cooled and stirred suspension of Lithium aluminum hydride (0.418 g, 0.011 moles) in 254 mL THF slowly over the period of 2 to 5 hours, the reaction mixture was heated to reflux for 2 - 4 hours, after the completion of reaction, the reaction mixture was poured on to the ice and the compound was extracted in ethyl acetate. The residue obtained was purified by flash chromatography (silica gel, EtOAc/hexanes, 2/8) to afford the compound, which was identified by IR, NMR and mass spectral analyses as the title compound. Description 20-35 (D20- D35) Using essentially the same procedure described in description-19 the compounds obtained in description 1-18 (D1-D18), were reduced to the corresponding derivatives. The list of compounds thus obtained is given below. The structure of compounds thus obtained were confirmed by IR, NMR and mass spectral analyses. List - 2 Description Mass Ion (M+H)* D 19 2-(4-Methylpipera2in-1 -ylmethyl)-1 H-indole 230 D20 2-(4-Methylpipera2in-1-ylmethyl)-5-methoxy-1 H-indole 260 D21 N-(1H-lndol-2-ylmethyl)-N,N',N'-trimethyl-ethane-1,2-diamine 232 D 22 3-Chloro-2-(4-methylpiperazin-1-ylmethyl)-1 H-indole 264 D 23 3-Chloro-2-(4-methylpiperazin-1-yl-methyl)-5-methoxy-1 H- 294 indole D 24 2-(4-Methylpipera2in-1-ylmethyl)-5-Ethoxy-1 H-indole. 274 D 25 2"(4-Methylpiperazin-1-ylmethyl)-5-Methylthio-1 H-indole. 276 D 26 2-(4-Methylpiperazin-1 -ylmethyl)-5-Methyl-1 H-indole. 244 D 27 2"(4-Methylpipera2in-1-ylmethyl)-5-lsopropyl-1 H-indole. 272 D 28 2-(4-Methylpiperazin-1-ylmethyl)-6,7-Dimethyl-1 H-indole. 258 0 29 2-(4-Methylpiperazin-1-ylmethyl)-5,7-Dimethyl-1H-indole. 258 D 30 N-(5-Ethoxy-1 H-indol-2-ylmethyl)-N,N',N'-trimethyl-ethane-1,2- 276 diamine. D31 N-(5-Methylthio-1H-indol-2-ylmethyl)-N,N\N'-trimethyl-ethane- 278 1,2-diamine. D32 N-(5-Methyl-1H-indol-2-ylmethyl)-N,N',N*-trimethyl-ethane-1,2- 246 diamine. D33 N-(5-lsopropyl-1H-indol-2"ylmethyl)-N,N\N'-trimethyl-ethane- ^m 1,2-diamine. D34 N.(6J-Dimethyl-imndol-2-ylmethyl)-N,N\N'-trimethyl-ethane- 260 1,2-diamine. D 35 N-(5,7-Dimethyl-1 H-indol-2-ylmethyl)-N,N',N'-trimethyl-ethane- 260 1,2-diamine. Example-1 : 1-Benzenesulfonyl-2-(4-methylpiperazin-1-ylmethyl)-1H-indole ; 2-(4-Methylpiperazin-1-ylmethyl)-1H-indole (2.59 g, 0.01 moles) in DMF (30 mL) was added slowly to a suspension of sodium hydride (0.26 g, 0.011 moles, (0.52 g of 50 % suspension in mineral oil)) in DMF (10 mL) maintaining the temperature below 10 °C. The mixture was stirred for 1 hr at 25 °C. and benzene sulfonyl chloride (1.76 g, 0.01 moles) was added at 10 °C drop-wise to the reaction mixture. The reaction mixture was further stirred for 1 hr at 25 ° C. After the completion of reaction (TLC), the reaction mixture was poured onto an ice-water mixture and extracted with ethyl acetate (20 mL x 2). The combined organic extracts were washed with water and brine and dried over sodium sulfate. Volatile impurities were distilled off under reduced pressure to obtain the crude residue. The residue obtained was purified by flash chromatography (silica gel, EtOAc/TEA, 9.9/0.1) to afford the compound, which was identified by IR, NMR and mass spectral analyses as the title compound. Alternatively, (1-Benzenesulfonyl-1 H-indol-2-yl)-(4-methylpiperazin-1-yl) methanone (Example 20) (0.8 g, 0.002 moles) in THF (10 mL) was treated with cooled and stirred suspension of LAH (0.04 g, 0.001 moles) in THF (10 mL) slowly over the period of 2 to 5 hours, the reaction mixture was heated to reflux for 2 - 4 hours, after the completion of reaction, the reaction mixture was poured on to the ice and the compound was extracted in ethyl acetate. The residue obtained was purified by flash chromatography (silica gel, EtOAc/hexanes, 2/8) to afford the compound, which was found to be identical to the compound synthesized earlier. IR spectra (cm"') : 1176, 1242, 1364, 1454; Mass (m/z) : 370 (M+H)*; ^H-NMR (Q ppm) : 2.25 (3H, s), 2.31 -2.56 (8H, m), 3.87 (2H, s), 6.55 (1H, s), 7.20-7.53 (6H, m), 8.08-8.12 (3H, m). Example - 2 : 1-(4-Fluorobenzenesulfonyl)-2-(4-methylpiperazin-1-ylmethyl)-1H- indole; Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm"^): 1162, 1240. 1378, 1451; Mass (m/z): 388 (M+H)^; ^H-NMR (5, ppm): 2.31 (3H, s), 2.41 -2.62 (8H, m), 3.87 (2H, s), 6.54 (1H, s), 7.04-7.32 (4H, m), 7.45-7.49 (1H, m), 8.03-8.19 (1H, dd), 8.20-8.23 (2H, m). Example - 3 : 1-(4-lsopropylbenzenesulfonyl)-2-(4-methylpiperazin-1-ylmethyl)- m-indole Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm"'): 1178,1240,1368, 1454; Mass (m/z): 412 (M+Hf; 'H-NMR (5, ppm) : 1.18 - 1.22 (6H, d), 2.26 (3H, s), 2.314 (4H, bs), 2.55 (4H, bs), 2.90 (1H, sep), 3.87 (2H, s), 7.20 (1H, s), 7.21 - 7.28 (4H, m), 7.44 - 7.54 (1H, m), 7.96 - 7.99 (2H, dd), 8.00 - 8.13 (1H, dd). Example - 4 : 1-(4-Methoxyben2enesulfonyl)-2-(4-methylpiperazin-1-ylmethyl)- IH-indole Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm^') : 1176,1262,1364,1454; Mass (m/z) : 400 (M+H)^; 'H-NMR (5, ppm) : 2.28 (3H, s), 2.35 - 2.59 (8H, m), 3.80 (3H, s), 3.88 (2H, s), 6.53 (1H, s), 6.83 - 6.87 (2H, dd), 7.19 - 7.27 (2H, m), 7.43 - 7.47 (1H, m), 8.06 - 8.12 (3H, m). Example - 5 : 1-(2-Bromo-4-methoxybenzenesulfonyl)-2-(4-methylpiperazin-1- ylmethyl)-1H-indole Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm"^) : 1150, 1290, 1369, 1455; Mass (m/z) : 478, 480 (M+H)*; ^H-NMR (5, ppm) : 2.21 (3H, s), 2.31 -2.50 (8H, m), 3.82 (5H, s), 6.62 (1H, s), 6.78 - 6.84 (1H, dd), 7.15 - 7.26 (3H, m), 7.48 - 7.56 (2H, m), 7.61 - 7.86 (1H, m). Example - 6 : 1-(4-Methoxybenzenesulfonyl)-5-methoxy-2-(4-methylpiperazin-1- ylmethyl)-1 H-indole Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm"'): 1163, 1263,1366, 1474; Mass (m/z): 430 (M+H)"^; ^H-NMR (5, ppm): 2.29 (3H, s), 2.41 - 2.59 (8H, m), 3.80 (3H, s), 3.81 (3H, s), 3.84 - 3.86 (2H, s), 6.46 (1H, s), 6.82 - 6.90 (4H, m), 7.96 - 8.03 (3H, m). Example - 7 : 1-(4-Methoxybenzenesulfonyl)-5-methoxy-2-(4-methylpiperazin-1- ylmethyl)-1 H-indole Hydrochloride salt Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm'^): 1163, 1268, 1369, 1475; Mass (m/z): 430 (M+H)*; ^H-NMR (5, ppm) : 3.03 (3H, s), 3.61 - 3.80 (8H, m), 3.82 (3H, s), 3.84 (3H, s), 4.80(2H,s), 6.98-8.10 (8H,m). Example - 8 : 1-(4-lsopropylbenzenesulfonyl-5-methoxy-2-(4-methylpiperazin-1- ylmethyl)-1 H-indole Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm"^): 1168, 1207, 1366, 1474; Mass (m/z): 442 (M+H)^; ^H-NMR (8, ppm) : 1.20 - 1.21 (6H, d), 2.27 (3H, s), 2.47 - 2.62 (8H, bm), 2.88 - 2.92 (1H, Sep.), 3.82 (3H, s), 3.84 (2H, s), 6.47 (1H, s), 6.88 - 6.92 (2H, m), 7.22 - 7.24 (2H, m). 7.88-7.91 (2H, m), 8.00-8.02 (1H, d). Example - 9 : 3-Chloro-1-(4-isopropylbenzenesulfonyl-5-methoxy-2-(4- methylpiperazin-1-ylmethyl)-1H-indole Using essentially the same procedure as described in example 1, above derivative was prepared. Melting range (^C) :118-120; IR spectra (cm*^) : 1172, 1213, 1368, 1452; Mass (m/z) : 476, 478 (M+H)^; ^H-NMR (5, ppm) : 1.19 - 1.23 (6H, d), 2.22 -2.60 (11, m), 2.88 - 2.95 (1H, sep.), 3.85 (3H, s), 3.95 (2H, s), 6.94 - 6.98 (2H, m), 7.00 - 7.22 (2H, m), 8.00 - 8.07 (3H. m). Example -10 : 1-(4-lsopropylbenzenesulfonyl-5-methoxy-2-(4-methylpiperazin-1- ylmethyl)-1H-indole Hydrochloride salt Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm"') : 1166, 1210, 1373, 1595; Mass (m/z) : 442 (M+H)^ ^H-NMR (6, Dppm) : 1.19 -1.22 (6H, d), 2.82 - 2.89 (1H, sep), 3.01 (3H, s), 3.33 - 3.34 (8H, bs), 3.82 (3H, bs), 4.75 (2H, s), 7.04 - 8.10 (8H, m). Example -11 : 3-Chloro-1-(4-methoxybenzenesulfonyl)-5-methoxy-2-(4- methylpiperazin-1-ylmethyl)-1H-indole Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm"') : 1166, 1215, 1370, 1480; Mass (m/z) : 464, 466 (M+H)^ ^H-NMR (5, ppm) : 2.29 (3H, s), 2.38-2.65 (8H, m), 3.81 (3H, s), 3.84 (3H, s), 3.96 (2H, s), 6.83 - 6.98 (4H, m), 7.97 - 8.01 (1H, dd), 8.16 - 8.20 (2H, dd). Example -12 : 3-Chloro-1-(4-methoxybenzenesulfonyl)-5-methoxy-2-(4- methylpiperazin-1-ylmethyl)-1H-lndole Hydrochloride salt Using essentially the same procedure as described in example 1, above derivative was prepared. Mass (m/z): 464 (M+H)"". Example -13 : 1-(2-Bromobenzenesulfonyl)-2-(4-methylpiperazin-1-ylmethyl)-1H- indole Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm"^): 1112, 1213, 1368, 1573; Mass (m/z): 478, 480 (M+H)". Example -14 : 1-(2-Bromobenzenesulfonyl)-3-chloro-2-(4-methylpiperazin-1- ylmethyl)-1H-indole Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm'^) : 1112, 1169, 1368, 1578; Mass (m/z): 512, 514, 516 (M+H)^ Example-15 : N-(1-BenzenesulfonyI-1H-indol-2-yl)methyl-N,N',N'- trimethylethylene-1,2-diamine Using essentially the same procedure as described in example 1, above derivative was prepared. Mass (m/z): 372 (M+H)"". Example -16 : N-(1-Ben2enesulfonyl)-3-bromo-1H-indol-2-yl)methyl-N,N',N'- trimethylethylene-1,2-diamine Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm'^): 1175,1262,1380,1448. Mass (m/z): 450, 452 (M+H)^; ^H-NMR (5, ppm) : 3.01-3.18 (9H, bs), 3.88-3.91 (4H, m), 4.88 (2H, s), 7.43-8.28 (9H, m). Example -17 : N-(1-(4-Methylben2enesulfonyl)-1H-indol-2-yl)methyl-N,N\N'- trimethylethylene-1,2-diamine Using essentially the same procedure as described in example 1, above derivative was prepared. Mass (m/z): 386 (M+H)"^. Example -18 : 1-(2-Bromo-4-methoxybenzenesulfonyl-1H-indol-2-yl)methyl- N,N',N'-trimethylethylene-1,2-diamine Using essentially the same procedure as described in example 1, above derivative was prepared. Mass (m/z): 480 (M+H)"". Example -19 : 1-((2-Bromo-4-methoxybenzenesulfonyl)-3-chloro-1H-indoi-2- yl)methyl-N,N',N'-trimethylethylene-1,2-diamine, hydrochloride. Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm"'): 1175, 1281, 1389, 1483. Mass (m/z): 514, 516 (M+H)^ ; ^H-NMR (6, ppm) : 3.06 - 3.31 (9H, bs), 3.90 (3H, s), 3.95 - 4.2 (4H, bs), 5.10 (2H, bs), 7.12 - 7.14 (1H, dd), 7.44 - 7.49 (1H, m), 7.58 - 7.68 (3H, m), 8.01 (1H, s), 8.12-8.25 (1H,d). Example - 20 : [1-Benzenesulfonyl-1H-indol-2-yl]-(4-methylpiperazin-1- yl)methanone 1-Benzenesulfonyl-indole-2-carboxylic acid (3.01 g, 0.01 moles) was stirred with oxalyl chloride (1,39 g, 0.011 moles) in 20 mL dichloromethane at 0 to 25 °C for 3 - 4 hours. After completion of the reaction (TLC), volatile substances were distilled off under the reduced pressure. The residue was taken in 20 mL dichloroethane, and to this stirred solution, was added N-methylpiperazine (1.1 g, 0.011 moles). The reaction mixture was further stirred for next 3 - 5 hours till the reaction completes (TLC). Reaction mixture was diluted with dichloromethane 20 mL), washed with water, brine and saturated solution of sodium bicarbonate. The organic layer was dried over sodium sulfate and the organic solvents were evaporated under vacuo. The product was purified using column chromatography on silica gel G stationary phase and suitable combinations of ethyl acetate and methanol in increasing gradient as the mobile phase. The residue obtained was identified by IR, NMR and mass spectral analyses as the title compound. Mass (m/z): 384 (M+H)*. Example - 21 : [1-(4-Fluorobenzenesulfonyl)-1 H-indol-2-yl]-(4-methylpiperazin-1- yl)methanone Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 402 (M+H)"^. Example - 22 : [1-(4-lsopropylbenzenesulfonyl)-1 H-indol-2-yl]-(4-methylpiperazin- 1-yl)methanone Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 426 (M+H)"". Example - 23 : [1-(4-Methoxybenzenesulfonyl)-1H-indol-2-yl]-(4-methylpiperazin- 1-yl)methanone Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 414 (M+H)"^. Example - 24 : [1-(2-Bromo-4-methoxybenzenesulfonyl)-1H-indol-2-yl]-(4- methylpiperazin-1-yl)methanone Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 492, 494 (M+H)^. Example - 25 : [1-(4-Methoxybenzenesulfonyl)-5-methoxy-1H-indol-2-yl]-(4- methylpiperazin-1-yl)methanone Using essentially the same procedure as described in example 20, above derivative was prepared. IR spectra (cm"^): 1164, 1264, 1371, 1641; Mass (m/z): 444 (M+H)^; ^H-NMR (8, ppm) : 2.34 (3H, s), 2.51 - 2.55 (4H, m). 3.44 (2H, bs), 3.77 (3H, s), 3.80 (3H, s), 3.85 - 3.87 (2H, bs), 6.59 (1H, s), 6.85 - 6.96 (4H, m), 7.89 - 7.91 (1H, d), 7.99-8.02 (2H.dd). Example - 26 : [1-(4-lsopropylbenzenesulfonyl)-5-methoxy-1H-indol-2-yl]-(4- methylpiperazin-1-yl)methanone Using essentially the same procedure as described in example 20, above derivative was prepared. Melting range C'C) :77.4-87.5, IR spectra (cm"'): 1165, 1222, 1371, 1642. Mass (m/z): 456 (M+H)^ ; ^H-NMR (6, ppm): 1.16-1.85 (6H, d) 2.34 (3H, s), 2.55 (4H, m), 2.86-2.89 (1H, sept.) 3.45 (2H, bs), 3.80 (3H, s), 3.87 (2H, bs), 6.59 (1H, s), 6.93-6.97 (2H. m), 7.28 (2H, dd), 7.9-7.93 (1H, d), 7.98-8.0 (2H, dd). Example - 27 : [3-Chloro-1-(4-isopropylbenzenesulfonyl)-5-methoxy-1H-indol-2- yl]-(4-methylpiperazin-1-yl)methanone Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 490 (M+H)^. Example - 28 : [3-Chloro-1-(4-Methoxybenzenesulfonyl)"5-methoxy-1H-indol-2-yl]- (4-methylpiperazin-1-yl)methanone Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 478, 480 (M+H)*. Example - 29 : [1-(2-Bromobenzenesulfonyl)-1H-indol-2-yl]-(4-methylpiperazin-1- yl)methanone Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 462, 464 (M+H)^ Example - 30 : [1-(2-Bromobenzenesulfonyl)-3-chloro-1 H-indol-2-yl]-(4- methylpiperazin-1-yl)methanone Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 494, 496, 498 (M+H)^ Example- 31 : 1-Benzenesulfonyl-1H-indole-2-carboxylicacid (2- dimethylaminoethyl)-N-methylamide Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 386 (M+H)"". Example - 32 : 1-Benzenesulfonyl-3-bromo-1H-indole-2-carboxylic acid (2- dimethylaminoethyl)-N-methylamide Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 464, 466 (M+H)^ Example - 33 : N-(1-(4-Methylbenzenesulfonyl)-3-bromo-1H-indole-2"Carboxylic acid (2-dimethylaminoethyl)-N-methylamide Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 478 (M+H)^. Example - 34 : 1-(2-Bromo-4-methoxybenzenesulfonyl-1H-indole-2-carboxylic acid (2-dimethylaminoethyl)-N-methylamide Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 494, 496 (M+H)^. Example - 35 : 1-(2-Bromo-4-methoxybenzenesulfonyl-3-bromo-1H-indole-2- carboxylic acid (2-dimethylaminoethyl)-N-methylamide Using essentially the same procedure as described in example 20, above derivative was prepared. Mass (m/z): 572, 574, 576 (M+H)^ Example- 36: (1-Benzenesulfonyl-5-methoxy-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)-methanone Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm'**) : 1177, 1372, 1444. 1634; Mass (m/z): 414 (M+H)^; ^H-NMR (5, Dppm): 2.36 (3H. s). 2,49 - 2.57 (4H, m). 3.47 (2H, bs), 3.79 (3H, s), 3.84 (2H, bs), 6.61 (1H, s), 6.93 - 9.96 (2H, ml 7.41 - 7.45 (2H, m), 7.50 - 7.54 (1H, m), 7.88 - 7.91 (1H, d), 8.07 - 8.09 (2H, d). Example - 37 : (1-(4'-Fluorobenzenesulfonyl-5-methyl-1H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm"'): 1182, 1376, 1440. 1641; Mass (m/z) : 416 (M+H)"; ^H-NMR (5, ppm) : 2.35 (3H, s), 2.39 (3H, s), 2.44 - 2.55 (4H, m), 3.45 (2H, bs), 3.86 (2H, bs), 6.61 (1H, s), 7.07 - 7.29 (4H, m), 7.85 - 7.87 (1H, d), 8.13 - 8.16 (2H, m). Example - 38 : (1-(4'-trifluoromethyl)benzenesulfonyl-5-methoxy-1H-indole-2-yl)- (4-Methylpiperazine-1-yl)-methanone Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm'^) : 1142,1378,1450,1628; Mass (m/z) : 482 (M+H)*; ^H-NMR (5, ppm) : 2.36 (3H, s), 2.48 - 2.58 (4H, m), 3.47 (2H, bs), 3.8 (3H ,s) 3.87 (2H, bs), 6.63 (1H, s), 6.94 - 6.99 (2H, m), 7.58 - 7.62 (1H, t),7.76-7.78 (1H, d).7.88-7.90 (1H, d), 8.33-8.35 (1H, d), 8.39 (IH.s). Example - 39 : (1-(3'-trifluoromethyl)benzenesulfonyl-5-methyl"1H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm"^) : 1180, 1380, 1438, 1640; Mass (m/z) : 466 (M+H)^; ^H-NMR (5, ppm) : 2.35 (3H, s), 2.39 (3H, s), 2.40 - 2.57 (4H, m), 3.47 (2H, bs), 3.87 (2H, bs), 6.62 (1H, s), 7.17 - 7.20 (1H. dd), 7.30 (1H, s), 7.58 - 7.62 (1H, t), 7.76 - 7.78 (1H, d), 7.85-7.87 (1 H, d), 8.36-8.38(1 H, d), 8.41 (1H, s). Example - 40 : (1-(Benzenesulfonyl-5-ethoxy-1 H-indole-2-yl)-(4-Methylpiperazine- 1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm'^) : 1090, 1223, 1364, 1453, 1630; Mass (m/z) : 428 (M+H)^; ^H-NMR (5, ppm) : 1.38 - 1.41 (3H, t), 2.17 (3H, s), 2.47 - 2.55 (4H, m), 3.46 (2H, bs), 3.87 (2H, bs), 3.57 - 4.05 (2H ,q). 6.60 (1H, s), 6.91 - 6.95 (2H, m), 7.41 - 7.45 (2H, m), 7.49 - 7.51 (2H, m), 7.88 - 7.90 (1H, d), 8.07 - 8.09 (2H, m). Example - 41 : (1-(4'-lsopropylbenzenesulfonyl-5-ethoxy-1 H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm'') : 1181, 1382, 1438, 1640; Mass (m/z): 470 (M+Hr. Example - 42 : (1-Benzenesulfonyl-5-thiomethyl-1 HHndole-2-yl)-(4- Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm"') : 794, 1261, 1374, 1437, 1641; Mass (m/z) : 430 (M+H)^; ^H-NMR (5, ppm) : 2.17 (3H, s), 2.35 (3H, s), 2.48 - 2.56 (4H, bm), 3.29 - 3.46 (2H, bs), 3.49 - 3.50 (2H, bs), 6.60 (1H, s), 7.26 " 7.28 (1H, dd), 7.38 - 7.54 (4H, m), 7.90 - 7.93 (1H, d), 8.10 - 8.12 (2H, m). Example - 43 : (1-(4'"Fluorobenzenesulfonyl-5-thiomethyl-1H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm"^) : 793, 1261, 1377, 1436, 1641; Mass (m/z) : 448 (M+H)^; ^H-NMR (8, ppm) : 2.17 (3H, s), 2.35 (3H, s), 2.49 - 2.55 (4H, bm), 3.27 - 3.45 (2H, bs), 3.49 - 3.50 (2H. bs), 6.61 (1H, s), 7.10 - 7.14 (2H, m), 7.27 - 7.29 (1H, dd), 7.39 - 7.39 (1H, d), 7.89 - 7.91 (1H, d), 8.14-8.17 (2H,m). Example - 44 : (1-(4'-lsopropylbenzenesulfonyl-5-thiomethyl-1H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm'^) : 802, 1174, 1378, 1466, 1633; Mass (m/z): 472 (M+H)^ Example - 45 : (1-(3'-trifluoromethyl)benzenesulfonyl-5-thiomethyl-1 H-indole-2-yl)- (4-Methylpiperazine-1-yl)-methanone Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm*^) : 801, 1173, 1378, 1467, 1632; Mass (m/z) : 498 (M+H)'; ^H-NMR (8, ppm) : 2.35 (3H, s), 2.49 (3H, s), 2.52 - 2.57 (4H, bm), 3.47 (2H, bs), 3.87 (2H, bs), 6.62 (1H, s), 7.26 -7.31 (2H, m), 7.60 - 7.64 (1H, t), 7.79 - 7.81 (1H, d), 7.89 - 7.91 (1H, d), 8.36 - 8.38 (1H,d),8.42(1H,s). Example - 46 : 5-methoxy -l-(Benzenesulfonyl) -2- (4-Methylpiperazine-1-yl)- methyl)-1H-indole. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm'^) : 1168, 1284, 1367, 1448; Mass (m/z): 400 (M+H)^; ^H-NMR (8, ppm): 2.26 (3H, s), 2.31 - 2.55 (8H, m), 3.81 (3H ,s), 3.83 (2H, s), 6.48 (1H, s), 6.87 - 6.91 (2H, m), 7.38-7.42 (2H, m),7.49-7.51 (1H, m).7.98-8.47 (3H. m). Example - 47 : 5-methoxy -1-(4'-Bromobenzenesulfonyl)-2-(4-Methylpiperazine-1- yl)-methyl)-1H-indole. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm"'): 1169, 1209, 1370, 1476; Mass (m/z): 478, 480 (M+H)^; ^H-NMR (8, ppm) : 2.30 (3H, s). 2.35-2.59 (8H. m), 3.81 (3H, s), 3.82 (2H, s), 6.48 (1H, s), 6.88-6.91 (2H, m), 7.51 -7.55 (2H, m), 7.93-7.96 (3H, m). Example - 48 : 5-methoxy -1-(3'-Trifluoro methyl-benzenesulfonyl)-2-(4- methylpiperazine-1-yl)-methyl)-1H-indole. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. Melting range (°C): 99.5-101.5; IR spectra (cm"'*): 1172, 1210,1375, 1476; Mass (m/z): 468 (M+H)^; ^H-NMR (5, ppm) : 2.23 (3H, s), 2.29-2.54 (8H, m), 3.82 (5H, s), 3.84 (3H, s), 6.50 (1H, s), 6.90-6.93 (2H, m) 7.53-7.57 (1H, t), 7.77-7.79 (1H. d), 7.95-7.97(1H, d), 8.21-8.25 (2H, m). Example - 49 : (1-(4'-Bromobenzenesulfonyl-5-methyl-1H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. Melting range (° C) : 76.8-79.7; IR spectra (cm'^): 1182, 1263, 1375,1640; Mass (m/z): 476, 478 (M+H)"; ^H-NMR (5, ppm) : 2.35 (3H, s), 2.39 (3H, s), 2.44-2.55 (4H, m), 3.44 (2H, bs), 3.86 (2H, bs), 6.61 (1H, s), 7.15-7.18 (1H, dd), 7.29 (1H, s), 7.55-7.58 (2H, dd), 7.84-7.87 (1H,d), 7.95-7.98 (2H,dd). Example - 50 : (1-(4'-Bromobenzenesulfonyl-5-methoxy-1 H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm'^): 1164, 1221, 1376, 1639; Mass (m/z) : 492, 494, (M+H)^; ^H-NMR (8, ppm) : 2.34 (3H, s), 2.45-2.54 (4H, m), 3.44 (2H, bs), 3.80 (3H, s), 3.85 (2H, bs), 6.62 (1H, s), 6.93 -6.97 (2H, m), 7.54-7.57 (2H, dd), 7.86-7.89 (1H. d), 7.93-7.96 (2H, dd). Example - 51 : (1-(4'-Fluorobenzenesulfonyl-5-methoxy-1H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared. Melting range (°C): 77-87.4, IR spectra (cm'') : 1163, 1223, 1375, 1639. Mass (m/z) : 432, 434, (M+H)^; ^H-NMR (8, ppm) : 2.35 (3H, s), 2.46-2.55 (4H, m), 3.45 (2H, bs), 3.80 (3H, s), 3.86 (2H, bs), 6.62 (1H, s), 6.93-6.97 (2H, m), 7.07-7.12 (2H, dd), 7.87-7.89 (1H, d), 8.11-8.14 (2H, m). Example - 52 : 3-Chloro-5-methoxy-1-(2'-bromobenzenesulfonyl )-2-yl-(4- methylpiperazine-1-yl-methyl)-1H-indol6 Using essentially the same procedure as described in example 1, above derivative was prepared. IR spectra (cm'^) : 1169, 1213, 1368, 1453; Mass (m/z) : 512, 514, 516 (M+Hf ; ^H-NMR (5, ppm) : 2.04 (3H, s), 2.02-2.45 (8H, m), 3.85 (3H, s), 3.88 (2H, s), 6.92-7.19 (2H, m), 7.20-7.39 (3H, m), 7.71-7.72 (1H, dd), 7.75-7.98 (1H, d). Example - 53 : (1-(4'-Methoxy)benzenesulfonyl-5-methyl-1 H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm"^): 1169, 1267, 1366, 1634; Mass (m/z) : 428 (M+H)^; 'H-NMR (5, ppm) : 2.34 (3H, s), 2.39 (3H, s), 2.51-2.54 (4H, bm), 3.42-3.49 (2H, bs), 3.77 (3H, s), 3.84-3.86 (2H, bs), 6.58 (1H, s), 6.85-6.89 (2H, m), 7.14-7.16 (1H, dd), 7.26-7.28 (1H, d), 7.87-7.89 (1H, d), 8.02-8.06 (2H, m). Example - 54 : (1-(3'-Trifluoromethyl)benzenesulfonyl-5-isopropyl-1 H-indole-2-yl)- (4-Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm"^): 1172, 1326, 1380, 1644; Mass (m/z) : 494 (M+H)*; ^H-NMR (5, ppm) : 1.24-1.26 (6H, d), 2.35 (3H, s), 2.45-2.56 (4H, bm), 2.93-3.00 (1H, Sep.), 3.48 (2H, bs), 3.87 (2H, bs), 6.64 (1H, s), 7.24-7.26 (1H, dd), 7.35-7.358 (1H, d), 7.59-7.63 (1H, t), 7.77-7.79 (1H, d), 7.88-7.90 (1H, d), 8.39-8.41 (1H, d), 8.44 (1H, s). Example - 55 : (1-(4'-lsopropyl)benzenesulfonyl-5-isopropyl-1 H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm"^) : 1172, 1262, 1373, 1644; Mass (m/z): 468 (M+H)". Example - 56 : (1-Benzenesulfonyl-5-isopropyl-1 H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm'^) : 1173, 1218, 1374, 1644; Mass (m/z) : 426 (M+H)* ; ^H-NMR (8, ppm) : 1.23-1.26 (6H, d), 2.34 (3H, s), 2.45-2.55 (4H, bm), 2.92-2.99 (1H, Sep.), 3.46-3.48 (2H, bs), 3.87 (2H, bs), 6.62 (1H, s), 7.20 -7.26 (2H, m), 7.340-7.343 (1H, d), 7.43-7.52 (3H, m), 7.89 -7.91 (1H,d), 8.13-8.15 (2H,m). Example - 57 : (1-{4'-Fluoro)benzenesulfonyl-5-isopropyl-1 H-indole-2-yl)-(4- Methylpipera2ine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using conresponding 1-unsubstituted indole. IR spectra (cm"'): 1174, 1218, 1377, 1642; Mass (m/z) : 444 (M+H)^; ^H-NMR (5, ppm) : 1.24-1.26 (6H, d), 2.34 (3H, s), 2.44-2.55 (4H, bm), 2.92-2.99 (1H, sep.), 3.46-3.49 (2H, bs). 3.86 (2H, bs), 6.62 (1H, s), 7.09-7.13 (2H, m), 7.21-7.26 (1H, m), 7.34-7.35 (1H, d). 7.87-7.90 (1H,d), 8.16-8.20 (2H,m). Example - 58 : (1-Ben2enesulfonyl-6,7-dimethyl-1H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone. Using essentially the same procedure as described in example 1, above derivative was prepared, using corresponding 1-unsubstituted indole. IR spectra (cm"^): 1175, 1218, 1377, 1640; Mass (m/z): 412 (M+H)^. We Claim, 1. A compound of the general formula (I), wherein A may be either a -CR11R12-, -C=0, -SO2-, -(CO)NH- or -C=S group; Q may be either a -CR11R12-, -C=0, -SO2-, -(CO)NH- or -C=S group; Ri, R2, R3, R4, R5, Re, R7. Rs, R9, R10, R11, R12, Ri4and R15 may be same or different and each independently represent hydrogen, halogen, 0x0, thio, perhaloalkyi, hydroxy, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (C1-C12)alkyl, (C2-C12)alkenyl, (C2- Ci2)alkynyl, (C3"C7)cycloalkyl, (C3-C7)cycloalkenyl, bicycloalkyi, bicycloaikenyl, (Cr Ci2)alkoxy, cyclo(C3-C7)alkoxy, aryl, aryloxy, aralkyi, aralkoxy, heterocyclyl, heteroaryl, heterocyclylalkyi, heteroaralkyi, heteroaryloxy, heteroaralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, heterocyclylalkoxycarbonyl, heteroaryjoxycarbonyj, hydroxyalkyi, aminoalkyi, monoalkylaminoalkyi, dialkylaminoalkyi, alkoxyalkyl, aryloxyalkyi, aralkoxyalkyl, alkylthio, thioalkyi, alkoxycarbonylamino, aryloxycarbonyiamino, aralkyloxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkylamidino, alkylguanidino, dialkylguanidino, hydrazine, hydroxylamino, carboxylic acid and its derivatives, sulfonic acids and its derivatives, phosphoric acid and its derivatives; or the adjacent groups like Ri and R2 or R2 and R3 or R3 and R4 or R5 and Re or Re and R? or R7 and Rs or Rs and R9 together with carbon atoms to which they are attached may form a five or a six membered ring, optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms; or Rn and R12 together with the carbon atoms to which they are attached may form a three to six membered ring, optionally containing one or more double bonds and optionally containing one or nnore heteroatoms selected from "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms; Ri3, Ri6 and R17 may be same or different and each independently represents hydrogen, substituted or unsubstituted groups selected from linear or branched (Cr Ci2)alkyl, (C2-C12)alkenyl, (C2-C12)alkynyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkenyl, bicycloalkyi, bicycloalkenyl, aryl, aralkyi, heteroaryl, heterocyclylalkyi; optionally R13 along with either R16 or R17 and the two nitrogen atoms may form a 5 to 7-membered heterocyclic ring, which may be further substituted with R14 and R15, and may have either one, two or three double bonds; and "n" is an integer ranging from 1 to 4, wherein the carbon chains which "n" represents may be either linear or branched. A compound according to Claim -1 which is selected from : 1-Ben2enesulfonyl-2-(4-methylpiperazin"1-ylmethyl)-1H-indole; 1-(4-Fluoroben2enesulfonyl)-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(4"lsopropylbenzenesulfonyl)-2-(4-methylpiperazin-1-ylmethyl)-1H"indole; 1-(4-Methoxyben2enesulfonyl)"2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(2-Bromo-4-methoxybenzenesulfonyl)"2-(4-methylpipera2in-1-ylmethyl)-1H-indole; 1-(4"Methoxyben2enesulfonyl)-5-methoxy-2-(4-methylpiperazin-1-ylmethyl)-1H- indole; 1-(4"Methoxyben2enesulfonyl)-5-methoxy-2-(4-methylpiperazin-1-ylmethyl)-1H-indole Hydrochloride salt; 1-(4"lsopropylbenzenesulfonyl-5-methoxy"2-(4-methylpipera2in-1-ylmethyl)-1H-indole; 3-Chloro-1-(4HSopropylbenzenesulfonyl-5-methoxy"2-(4-methylpiperazin-1-ylmethyl)-IH-indole; 1-(4"lsopropy!benzenesulfonyl-5-methoxy-2-(4-methylpiperazin-1-ylmethyl)-1H-indole Hydrochloride salt; 3-Chloro-1-(4-methoxyben2enesulfonyl)-5-methoxy-2-(4-methylpipera2in-1-ylmethyl)-1H-indole; 3-Chloro-1-(4-methoxybenzenesulfonyl)-5-methoxy-2-(4-methylpiperazJn-1-ylmethyl)-1H-indole Hydrochloride salt; 1-(2-Bromobenzenesulfonyl)-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(2-Bromobenzenesulfonyl)-3-chlorO"2-(4-methylpiperazin-1-ylmethyl)-1H-indole; N-(1-Benzenesulfonyl-1H-indol-2-yl)methyl-N,N',N'-trimethylethylene-1,2-diamine; N-(1-Ben2enesulfonyl)-3"bromo-1H-indol-2-yl)methyl"N,N',N'-trimethylethylene-1,2-diamine; N-(1-(4-Methylbenzenesulfonyl)-1H-indol-2-yl)methyl-N,N',N'-trimethylethylene-1,2- amine; (2-Bromo-4-methoxybenzenesulfonyl-1H-indol-2-yl)methyl-N,N\N'-trimethylethylene-1,2-diamine; 1-(2-Bromo-4-methoxybenzenesulfonyl-3-chloro-1H-indol-2-yl)methyl-N,N',N'-trimethylethylene-1,2-diamine, hydrochloride; [1-Ben2enesulfonyl-1H-indol-2-yl]-(4-methylpiperazin"1-yl)methanone; [1-(4-Fluorobenzenesulfonyl)-1H-indol-2-yl]-(4-methylpiperazin-1-yl)methanone; [1-(4-lsopropylbenzenesulfonyl)-1H-indol-2-yl]-(4-methylpiperazin-1-yl)methanone; [1-(4-Methoxybenzenesulfonyl)-1H-indol-2-yl]-(4-methylpiperazin-1-yl)methanone; [1-(2-Bromo-4-methoxybenzenesulfonyl)-1H-indol-2-yl]-(4-methylpiperazin-1- yl)methanone; [1-(4-Methoxybenzenesulfonyl)-5-methoxy-1H-indol-2-yl]-(4-methylpiperazin-1- yl)methanone; [1-(4-lsopropylbenzenesulfonyl)-5-methoxy-1H-indol-2-yl]-(4-methylpiperazin-1- yl)methanone; [3-Chloro-1-(4-isopropylbenzenesulfonyl)-5-methoxy-1H-indol-2"yl]-(4- methylpiperazin-1-yl)methanone; [3-ChlorO"1-(4-MethoxybenzenesuIfonyl)-5-methoxy-1H-indol-2-yl]-(4- methylpiperazin-1-yl)methanone; [1-(2-Bromobenzenesulfonyl)-1H-indol-2-yl]-(4-methylpiperazin-1-yl)methanone; [1-(2-Bromobenzenesulfonyl)-3"Chloro-1H-indol-2-yl]-(4-methylpiperazin-1- yl)methanone; 1-Benzenesulfonyl-1H-indole-2-carboxylic acid (2-dimethylaminoethyl)-N- methylamide; 1-Benzenesulfonyl-3-bromo-1H-indole-2-carboxylic acid (2-dimethylaminoethyl)-N- methylamide; N-(1 -(4-Methylbenzenesulfonyl)-3-bromo-1 H-indole-2-carboxylic acid (2- dimethylaminoethyl)-N-methylamide; 1-(2-Bromo-4-methoxybenzenesulfonyl-1 H-indole-2-carboxylic acid (2- dimethylaminoethyl)-N-methylamide; 1-(2-Bromo-4-methoxybenzenesulfonyl-3-bromo-1 H-indole-2-carboxylic acid (2- dimethyIaminoethyl)-N-methylamide; (1-Benzenesulfonyl-5-methoxy-1HHndole-2-yl)-(4-l\/lethylpiperazine-1-yl)-methanone; (1-(4'-Fluoro - benzenesulfonyl-5-methyI-1 HHndole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-(4'-trifluoromethyl)benzenesulfonyl-5-methoxy-1H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone; (1-(3'-trifluoromethyl)benzenesulfonyl-5-methyl-1H-indole-2-yl)-(4-Methyl^ 1-yl)-methanone; (1-(Benzenesulfonyl-5-ethoxy-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)-methanone; (1-(4'-lsopropylbenzenesulfonyl-5-ethoxy-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-Benzenesulfonyl"5-thiomethyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-(4'-Fluorobenzenesulfonyl-5-thiomethyl-1H-indole-2-yl)-(4-Methylpiperazine-^ methanone; (1-(4'-lsopropylbenzenesulfonyl-5-thiomethyl-1H-indole-2-yl)-(4-Methylpiperazine-1^ yl)-methanone; (1-(3'-trifluoromethyl)benzenesulfonyl-5-thiomethyl-1H-indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone; 5-methoxy -l-(Benzenesulfonyl) -2- (4-Methylpiperazine-1-yl)-methyl)-1HHndole; 5-methoxy -1-(4'-Bromobenzenesulfonyl) -2- (4-Methylpiperazine-1-yl)-methyl)-1H- indole; 5-methoxy-1-(3'-Trifluoro methylbenzenesulfonyl)-2-(4-methylpiperazine-1-yl)- methyl)-1H-indole; (1-(4'-Bromo-benzenesulfonyl-5-methyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yO methanone; (1-(4'-Bromobenzenesulfonyl-5-methoxyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-(4'-Fluoro-benzenesulfonyl-5-methoxyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; 3-Chloro-5-methoxy-1-(2'-bromobenzenesulfonyl)-2-yl-(4-methylpiperazine-1-yl methyl )-1H-indole; (1-(4'-Methoxy)benzenesulfonyl-5-methyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-(3'-Trifluoromethyl)benzenesulfonyl-5-isopropyl-1H"indole-2-yl)-(4- Methylpiperazine-1-yl)-methanone; (1-(4'-lsopropyl)benzenesulfonyl-5-isopropyl-1H-indole-2-yl)-(4-Methylpiperazine-1- yl)-methanone; (1-Benzenesulfonyl-5-isopropyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)-methanone; (1-(4'-Fluoro)benzenesulfonyl-5-isopropyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; (1-Benzenesulfonyl-6,7-dimethyl-1HHndole-2-yl)-(4-Methylpiperazine-1-yl)- methanone; 1-Benzenesulfonyl-5-ethyl-2"(4-methylpiperazin-1-ylmethyl)-1l+indole; 1-(4-Fluorobenzenesulfonyl)-5-ethyl-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(4-lsopropylbenzenesulfonyl)-5-ethyl-2-(4-methylpiperazin-1-ylmethyl)-1H"indole; 1-(4-Methoxybenzenesulfonyl)-5-ethyl-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(2-Bromo-4-methoxybenzenesulfonyl)-5-ethyl-2-(4-methylpiperazin-1-ylmethyl)-1H- indole; 1-Benzenesulfonyl-5-isopropoxy-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(4-Fluorobenzenesulfonyl)-5- isopropoxy -2-(4-methylpiperazin-1-ylmethyl)-1 H- indole; 1-(4-lsopropylbenzenesulfonyl)-5" isopropoxy -2-(4-methylpiperazin-1-ylmethyl)"1 H- indole; 1-(4-Methoxybenzenesulfonyl)-5- isopropoxy -2-(4-methylpiperazin-1-ylmetliyl)-1 H- indole; 1-(2-Bromo-4-methoxybenzenesulfonyl)-5- isopropoxy-2-(4-methylpiperazin-1- ylmethyl)-1H-indole; 1-Benzenesulfonyl-5"ethylthio-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(4"Fluoroben2enesulfonyl)-5- ethylthio -2-(4-methylpiperazin-1-ylmethyl)-1 H-indole; 1-(4"lsopropylbenzenesulfonyl)-5- ethylthio -2-(4-methylpiperazin-1-ylmethyl)-1 H- indole; 1-(4-Methoxybenzenesulfonyl)-5- ethylthio -2-(4-methylpiperazin-1-ylmethyl)-1 H- indole; 1-(2-Bromo-4-methoxybenzenesulfonyl)-5-ethylthio-2-(4-methylpiperazin-1- ylmethyl)-1 H-indole; 1-Benzenesulfonyl-5-benzyloxy-2-(4-methylpiperazin-1-ylmethyl)-1 H-indole; 1-(4-Fluoroben2enesulfonyl)-5-benzyloxy-2-(4-methylpiperazin-1-ylmethyl)-1 H-indole; 1-(4-lsopropylbenzenesulfonyl)-5- benzyloxy -2-(4-methylpipera2in-1-ylmethyl)-1 H- indole; 1-(4-Methoxybenzenesulfonyl)-5- benzyloxy -2-(4-methylpiperazin-1-ylmethyl)-1 H- indole; 1-(2-Bromo-4-methoxybenzenesulfonyl)-5-benzyloxy-2-(4-methylpiperazin-1-ylmethyl)-1 H-indole; 1-Benzenesulfonyl-5-cyclopentyloxy-2-(4-methylpiperazin-1-ylmethyl)-1 H-indole; 1-(4-Fluoroben2enesulfonyl)-5-cyclopentyloxy-2-(4-methylpiperazin-1-ylmethyl)-1H- indole; 1-(4-lsopropylbenzenesulfonyl)-5-cyclopentyloxy-2-(4-methylpiperazin-1-ylmethyl)-1 H-indole; 1-(4-Methoxyben2enesulfonyl)-5-cyclopentyloxy-2-(4-methylpiperazin-1-ylmet^ 1H-indole; 1-(2-Bromoben2enesulfonyl)-5-cyclopentyloxy-2-(4-methylpiperazin-1-ylmethyl^ indole; 1"Ben2enesulfonyl-3-bromO"5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; 1-(4-Fluoroben2enesulfonyl)-3-bromo-5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)-1H- indole; 1-(4-lsopropylbenzenesulfonyl)-3-bromo-5-ethoxy"2-(4-methylpip6ra2in-1-ylmethyl)- 1 H-indole; 1-(4-Methoxybenzenesulfonyl)-3-bromo-5-ethoxy"2-(4-methylpiperazin-1-ylmethyl)" 1 H-indole; 1-(2-Bromobenzenesulfonyl)-3-bromO"5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)-1H- indole; 1-Ben2enesulfonyl-3-chloro-5-ethoxy-2-(4-methylpipera2in-1"ylmethyl)-1 H-indole; 1-(4-Fluorobenzenesulfonyl)-3-chloro-5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)- 1 H-indole; 1-(4-lsopropylbenzenesulfonyl)-3-chloro-5-ethoxy"-2-(4-methylpiperazin-1-ylmethyl)- 1 H-indole; 1-(4-Methoxyben2enesulfonyl)-3-chloro-5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)- 1 H-indole; 1-(2-Bromobenzenesulfonyl)"3-chloro-5-ethoxy-2-(4-methylpiperazin-1-ylmethyl)-1H-indole; (1-(4'-Bromo-benzenesulfonyl-5-ethyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)-methanone; (1-(2'-Bromo-benzenesulfonyl-5-ethyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)-methanone; (1-(4'-trifluoromethylbenzenesulfonyl-5-ethyl-1H-indole-2-yl)-(4-Methylpiperazine-1-yl)-methanone; (1-(4'-trifluoromethylbenzenesulfonyl-5-ethoxyl-1H-indole-2-yl)-(4-Methylpipera2ine-1-yl)-methanone; and (1-(4'-fluoroben2enesulfonyl-5-ethoxyl-1H-indole-2-yl)-{4-Methylpipera2ine-1-yl)-methanone; and their pharmaceutically acceptable salts, polymorphs and solvates. 3. A pharmaceutical composition comprising either of a pharmaceutically acceptable carrier, diluent, excipients or solvate along with a therapeutically effective amount of a compound according to Claim-1, its derivatives, its analogs, its tautomeric forms, its stereoisomers, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates. A pharmaceutical composition according to Claim-3, in the form of a tablet, capsule, powder, synjp, injectible, solution or suspension. Use of compound of general formula (I), as defined in Claim-1 or a pharmaceutical composition as defined in Claim-3 for preparing medicaments. Use of compound of general formula (I), as defined in Claim-1 or a pharmaceutical composition as defined in Claim-3 for the treatment where a modulation of 5-HT activity is desired. Use of a compound as claimed in Claim-1 for the manufacture of a medicament for the treatment and/or prevention of clinical conditions for which a selective action on 5-HT receptors is indicated. Use of a compound as claimed in Claim-1 for the treatment and/or prevention of clinical conditions such as anxiety, depression, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders, ADHD (Attention Deficient Disorder/ Hyperactivity Syndrome), personality disorders, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse, panic attacks, sleep disorders and also disorders associated with spinal trauma and /or head injury. Use of a compound as claimed in Claim-1 for the treatment of mild cognitive impairment and other neurodegenerative disorders like Alzheimer's disease. Parkinsonism and Huntington's chorea. Use of a compound as claimed in Claim-1 for the treatment of certain Gl (Gastrointestinal) disorders such as IBS (Irritable bowel syndrome) or chemotherapy induced emesis. Use of a compound as claimed in Claim-1 to reduce morbidity and mortality associated with the excess weight. Use of a radiolabelled compound as claimed in Claim-1, as a diagnostic tool for modulating 5-HT receptor function. Use of a compound as claimed in Claims 1 in combination with a 5-HT re-uptake inhibitor, and / or a pharmaceutically acceptable salt thereof. A compound of the general formula (1), its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts and its pharmaceutically acceptable solvates for preparing a medicament. A method for the treatment and/or prophylaxis of clinical conditions such as anxiety, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders, ADHD (Attention Deficient Disorder/ Hyperactivity Syndrome), personality disorders, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse, panic attacks, sleep disorders and also disorders associated with spinal trauma and /or head injury, which comprises administering to a patient in need thereof, an effective amount of a compound of general formula (I) as claimed in Claim-1. A method for the treatment and/or prophylaxis of mild cognitive impairment and other neurodegenerative disorders like Alzheimer's disease, Parkinsonism and Huntington's chorea which comprises administering to a patient in need thereof, an effective amount of a compound of general formula (I) as claimed in Claim-1. A method for the treatment of certain Gl (Gastrointestinal) disorders such as IBS (Irritable bowel syndrome) or chemotherapy induced emesis using a compound of general formula (I) as claimed in Claim-1. A method to reduce morbidity and mortality associated with the excess weight using a compound of general formula (I) as claimed in Claim-1. A process for the preparation of compound of formula (I), which comprises of anyone of the following schemes: Scheme -1 : reacting a compound of formula (II) given below. Where Ri, R2, R3, R4, Rio and A are as defined in relation to formula (I) , X is halogeno, for example, a chloro, bromo or iodo; R represents either of a suitable N-protecting group such as acetyl, triflouroacetyl, trityl, t-butyloxycarbonyl (t-BOC) or a group such as, where R5, Re, R7. Rs and R9 are as defined eariier; with a compound of formula (III) or its acid addition salt. where R13, R14, R15. R16 and R17 are as defined in relation to compound of formula (I) or precursor thereof; and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (1); and/or, ii) removing any protecting groups; and/or, iii) forming a phamriaceutically acceptable salt or prodrug thereof; Scheme - 2 : reacting a compound of formula (IV) given below, Scheme - 3 : wherein A, Ri, R2, R3, R4, Rio, R13, Ri4, R15, Rieand Riyare as defined in relation to formula (I); with anyone of the following compound represented by a general formula (V), where R5, Re, R7, Rs and Rg, are as defined in relation to formula (I) and X is a halogeno, preferably chloro or bromo; Scheme - 4 : reacting a compound of formula (Vl) given below, where Ri, R2, R3, R4, and Rioare as defined in relation to formula (I), R represents either of a suitable N-protecting group such as acetyl, triflouroacetyl, or a group such as, where R5, Re, R7. Rs and Rgare as defined earlier; with a compound of formula (III) or its acid addition salt. where R13, R14, R15, Rieand Riyare as defined in relation to compound of formula (I) or precursor thereof; by standard peptide coupling for example using bis(2-oxo-3-oxazolidinyl) phosphoric chloride (BOP-CI); Scheme - 5 : reacting a compound of formula (VII) given below, \ - --f wherein Ri, R2, R3, R4 and Rio are as defined in relation to formula (I), X is a halogeno group, such as chloro, bromo or iodo; while R represents either of a suitable N-protecting group such as acetyl, triflouroacetyl, benzyl, trityl, t-butyloxycarbonyl (t-BOC) or a group such as, I where R5, Re, R7, Rs and Rgare as defined earlier, with a compound of formula (III) or its acid addition salt. wherein R13, R14, R15, Rie and R17 are as defined in relation to compound of formula (I) or precursor thereof; in suitable anhydrous solvent. Scheme - 6 : few compounds of formula (I) where A = -CH2-, can be obtained by carrying out chemical, catalytic or enzymatic reduction of the compounds of formula (I) where A = -C=0 using the known procedures. 20. A process according to Claim-19, comprising of carrying out one or more of the following optional steps: i) removing any protecting group; ii) resolving the racemic mixture into pure enantiomers by the known methods and iii) preparing a pharmaceutically acceptable salt of a compound of formula (I) and/or iv preparing a phamnaceutically acceptable prodrug thereof. 21. The novel intermediate of general formula (IV) is defined as below, wherein A may be either a -CR11R12-, -0=0, -SO2-, -(CO)NH- or -C=S group, Ri, R2, R3, R4, R10, R11, Ri2> Ri4 and R15 may be same or different and each independently represent hydrogen, halogen, 0x0, thio. perhaloalkyi, hydroxy, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (C1-C12)alkyl, (C2"Ci2)alkenyl, (C2-C12)alkynyl, (C3- C7)cycloalkyl, (C3-C7)cycloalkenyl, bicydoalkyl, bicycloalkenyl, (Ci-Ci2)alkoxy, cyclo(C3-C7)alkoxy, aryl, aryloxy, aralkyi, aralkoxy, heterocyciyl. heteroaryl, heterocyclylalkyi, heteroaralkyi, heteroaryloxy, heteroaralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, heterocyclylalkoxycarbonyl, heteroaryloxycarbonyl, hydroxyalkyi, aminoalkyi, monoalkylaminoalkyi, dialkylaminoalkyi, alkoxyalkyl, aryloxyalkyi, aralkoxyalkyi, alkylthio, thioalkyi, alkoxycarbonylamino, aryloxycarbonylamino, aralkyloxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkylamidino, alkylguanidino, dialkylguanidino, hydrazine, hydroxylamino, carboxylic acid and its derivatives, sulfonic acids and its derivatives, phosphoric acid and its derivatives; or the adjacent groups like Ri and R2 or R2 and R3 or R3 and R4 together with carbon atoms to which they are attached may form a five or a six membered ring, optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms; or R11 and R12 together with the carbon atoms to which they are attached may form a three to six membered ring, optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms; Ri3, R16 and R17 may be same or different and each independently represents hydrogen, substituted or unsubstituted groups selected from linear or branched (d-Ci2)alkyl, (C2-C12)alkenyl, (C2-C12)alkynyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkenyl, bicycloalkyi, bicycloalkenyl, aryl, aralkyi, heteroaryl, heterocyclylalkyi; alternatively Ri3 along with either R16 or R17 and the two nitrogen atoms may form a 5-, 6- or 7-membered heterocyclic ring, which may be further substituted with R14 and R15, and may have either one, two or three double bonds, with the proviso that, When R13 along with R16 together with the intervening nitrogens form a piperazine or a substituted piperazine ring, then R17 is never aryl substitutent; and "n" is an integer ranging from 1 to 4, wherein the carbon chains which "n" represents may be either linear or branched. 22. A compound of the general formula (I), substantially as described hereinbefore and with reference to the foregoing examples. 23. An intermediate of general formula (IV), substantially as described hereinbefore and with reference to the foregoing examples. 24. A process for the preparation of compound of formula (I), substantially as described hereinbefore and with reference to the foregoing examples. 25. A pharmaceutical composition, substantially as described hereinbefore and with reference to the foregoing examples. |
|---|
459-CHE-2003 CLAIMS 08-09-2009.pdf
459-che-2003 correspondence others.pdf
459-CHE-2003 EXAMINATION REPORT REPLY RECIEVED 08-09-2009.pdf
459-che-2003 pct search report.pdf
459-che-2003-correspondnece-others.pdf
459-che-2003-correspondnece-po.pdf
459-che-2003-description(complete).pdf
459-che-2003-description(provisional).pdf
| Patent Number | 243298 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indian Patent Application Number | 459/CHE/2003 | |||||||||||||||
| PG Journal Number | 41/2010 | |||||||||||||||
| Publication Date | 08-Oct-2010 | |||||||||||||||
| Grant Date | 05-Oct-2010 | |||||||||||||||
| Date of Filing | 06-Jun-2003 | |||||||||||||||
| Name of Patentee | SUVEN LIFE SCIENCES LIMITED | |||||||||||||||
| Applicant Address | SERENE CHAMBERS, ROAD NO 7,BANJARA HILLS, HYDERABAD, | |||||||||||||||
Inventors:
|
||||||||||||||||
| PCT International Classification Number | A61K 31/405 | |||||||||||||||
| PCT International Application Number | N/A | |||||||||||||||
| PCT International Filing date | ||||||||||||||||
PCT Conventions:
|
||||||||||||||||